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The IDRS sample is a sentinel group of people 
aged 18 years or older who injected illicit drugs 
at least once monthly in the preceding six 
months and resided in the capital cities of 
Australia. Participants were recruited via 
advertisements in needle syringe programs 
and other harm reduction services, as well as 
via peer referral. The results are not 
representative of all people who use illicit 
drugs, nor of use in the general population. 
Data were collected in 2020 from June-
September: subsequent to COVID-19 
restrictions on travel and gatherings in 
Australia. Interviews were mostly delivered 
via phone rather than face-to-face though 
some participants were interviewed face-to-
face in Tasmania and the Northern 
Territory. This should be factored into all 
comparisons of data from the 2020 sample 
relative to previous years.  
Sample Characteristics 
The IDRS sample in 2020 (N=884) was 
predominantly identified as male (59%) with a 
mean age of 44, consistent with the national 
profile in previous years. This sample had more 
females participating in 2020 compared to 
2019. Half of the participants (50%) reported 
that their drug of choice was heroin, an 
increase relative to 2019 (45%). Heroin and 
methamphetamine were the drugs injected 
most often in the past month (46% and 41%, 
respectively).  
COVID-19 Impact 
This brief section was included to summarise 
data collected specifically related to COVID-19 
and associated restrictions; subsequent 
sections reflect standard annual reporting. 
One-fifth (20%) of the national sample had 
been tested for SARS-CoV-2, though no 
participants had been diagnosed with COVID-
19. Since the beginning of March 2020, most 
participants (89%) had practiced social 
distancing and 70% had undergone home 
isolation. Over one-third (36%) of participants 
reported injecting drugs at a different frequency 
in the past month as compared to February 
2020; whereby 25% reported greater 
frequency of injection, with 11% reporting a 
reduced frequency.  One-tenth (12%) reported 
a change in the main drug injected in February 
versus the past month (subsequent to COVID-
19 restrictions). Nearly half (48%) the 
participants reported a perceived decrease in 
the use of methamphetamine since March, with 
57% of these participants citing ‘decreased 
availability’ as the primary reason. Smaller 
numbers reported an increase in alcohol (27%) 
and cannabis (25%), mainly cited as due to 
‘boredom/less things to occupy time’. Most 
participants reported that crystal 
methamphetamine and heroin had increased 
in price since the beginning of March 2020 
(91% and 62%, respectively). Furthermore, 
crystal methamphetamine and heroin were 
most commonly reported to have decreased in 
perceived purity (59% and 50%, respectively). 
Crystal methamphetamine and morphine were 
the drugs most commonly cited as having 
decreased in availability (71% and 57%, 
respectively). Almost one-third (32%) of 
participants rated their mental health in the 
past four weeks as ‘being worse’ compared to 
February, and 50% reported ‘similar’. Of those 
on opioid agonist treatment since March 2020 
(n=373), 25% reported an increase in take-
away doses. Whilst the majority of participants 
reported ‘no change’ when commenting on 
changes related to their injecting practices 
since March 2020, 9% reported an increase in 
re-using their own needles, and 13% reported 
injecting alone more. Over one-quarter (28%) 
of participants reportedly sought information on 
how to reduce the risk of acquiring COVID-19 
or avoiding impacts of restrictions on drug 
acquisition and use. The majority (82%) of 
participants reported engaging in various harm 
reduction behaviours to reduce the risk of 
acquiring COVID-19 or impacts of COVID-19 
restrictions while using or obtaining drugs.  







Recent (i.e., past six month) use of any heroin 
increased from 55% in 2019 to 63% in 2020. 
There was large jurisdictional variation (e.g., 
n≤5 of participants in the NT sample versus 
86% in the VIC sample). Median frequency of 
use in 2020 was 96 days in the past six months. 
Significantly more participants perceived 
heroin to be of ‘low’ purity and ‘difficult’ to 
obtain in 2020 compared to 2019. 
Methamphetamine 
Recent use of any methamphetamine has 
fluctuated over the years. In 2020, 72% 
reported recent use, significantly lower than 
78% in 2019. The majority reported use of the 
crystal form of methamphetamine (71%) with 
smaller numbers reporting recent use of 
powder (20%) and base (8%). Frequency of 
use remained stable relative to 2019 (median 
of 48 days for 2019 and 2020). In 2020, there 
was a significant increase in the price of a point 
and gram of crystal methamphetamine, relative 
to 2019 ($50 versus $100 and $250 versus 
$500, respectively). One-third reported crystal 
methamphetamine was ‘difficult’ to obtain, the 
highest percentage since monitoring began. 
Cocaine 
Recent use of cocaine and frequency of use 
has generally decreased amongst the national 
sample since the beginning of monitoring (35% 
in 2001). In 2020, a significant increase was 
observed, relative to 2019 (17%; 13% in 2019).  
Cannabis 
Recent use of cannabis was reported by the 
lowest per cent since monitoring began (67%) 
and was also a significant decrease relative to 
2019 (74%). Frequency of use, however, was 
similar to 2019 at a median of 160 days (130 
days in 2019). Nearly half the consumers 
(48%) reported using cannabis daily (46% in 
2019). The price of an ounce of hydroponic and 
bush cannabis had both significantly 
increased, relative to 2019.  
Pharmaceutical Opioids 
Non-prescribed use of most forms of 
pharmaceutical opioids has either remained 
stable or significantly declined since monitoring 
of each opioid first began. In 2020, morphine 
was the most common pharmaceutical opioid 
used in a non-prescribed context (15%). Six 
per cent of the national sample reported recent 
non-prescribed fentanyl use, stable from 9% in 
2019. There was a significant decrease of 
those reporting recent use of non-prescribed 
codeine in 2020. relative to 2019 (4% versus 
9% in 2019).  
Other Drugs 
Use of NPS has remained low and stable over 
the period of monitoring. In 2020, slightly less 
participants reported recent use (8% versus 
11% in 2019). Use of ‘new’ drugs that mimic 
the effects of cannabis and opioids were 
reported by 5% and 1%, respectively. Recent 
use of e-cigarettes (13%), tobacco (89%), 
alcohol (54%), anti-psychotics (6%) and 
pregabalin (14%) had significantly declined 
compared to 2019 reports. One-in-ten reported 
recent use of GHB /GBL/1,4-BD. 
Drug-Related Harms and Other Associated 
Behaviours 
Nearly one in five participants (18%) reported 
overdosing on any drug in the preceding year, 
most commonly heroin. One in three (34%) had 
been trained in naloxone administration and 
5% of the sample had been resuscitated with 
naloxone by somebody trained through the 
take-home naloxone program. In 2020, 5% of 
participants reported receptive sharing of a 
needle or syringe and 9% reported distributive 
sharing in the past month. Significantly fewer 
participants reported to have experienced 
injection-related problems in 2020. Nearly half 
of the sample were currently in any drug 
treatment (48%), an increase relative to 2019 
(42%). Self-reported mental health problems in 
the past six months and any criminal activity in 
the past month remained stable from 2019 
(47% and 40%, respectively). 
2020 SAMPLE CHARACTERISTICS
NALOXONE
OTHER HARMS AND HELP-SEEKING 
INJECTING RELATED RISKS AND HARMS
In 2020, 884 people from all 
Australian capital cities 
participated in IDRS interviews.
The mean age in 2020 was 44, 
and 59% identified as male.
IDRS participants’ knowledge of the 
take home naloxone 
program, nationally.
In the 2020 sample, 6% had 
experienced a non-fatal stimulant 
overdose in the previous 12 months.
In the 2020 IDRS sample, 13% had a 
non-fatal opioid overdose in the last 
year. Heroin was the most 
commonly cited opioid related to 
non-fatal overdose.
Of those who reported ever accessing 
naloxone, 34% received 
intramuscular naloxone and 14%  
intranasal naloxone.
Of those who reported having heard of 
naloxone, 27% had used naloxone to 
resuscitate someone who had 
overdosed.
In the 2020 sample, 88% were 
unemployed and 12% had no fixed 
address.
In the sample, 47% self reported a 
mental health problem in the six months 
prior to interview, and 48% were 
in drug treatment at the time of inter-
In 2020, 5% of the IDRS sample 
reported receptive needle sharing, 
and 9% reported distributive needle 
sharing.
  
The number of people who re-used 
their own needles was stable from 
2019 to 2020 (44%).
Participants were recruited on the 
basis that they had injected drugs 
at least monthly in the previous 
6 months.
In the IDRS sample, 5% said they 
had been resusciated with naloxone 
by a peer.
In the sample, 31% reported being 
diagnosed with depression and 
24% with anxiety in the past six 
months.
In 2020, just under one third (29%) of the 
national sample reported having
an injection-related health issue 
in the month preceding interview.













































Past 6 month use of heroin 
increased to 63% in the 2020 
IDRS sample (55% 2019).
Of those who had recently 
consumed heroin, almost 
4 in 5 used it weekly or more 
often.
Past 6 month use of any 
methamphetamine was stable 
at 72% of the 2020 IDRS 
sample (78% in 2019).
Past 6 month use of 
non-prescribed pregabalin 
was stable at 18% in the 2019 
IDRS sample to 14% in 2020.
Past 6 month use of non-pre-
scribed morphine was stable at 
18% in the 2019 IDRS sample 
and 15% in 2020.
Of the entire sample, 20% had recently 
consumed powder, and 71% crystal 
methamphetamine.
Injection was the main route
of administration for powder (93%) and 
crystal (95%) among those who had 
consumed each form.
Past 6 month use of 
non-prescribed fentanyl 
was stable at 9% in the 2019 
IDRS sample to 6% in 2020.
Past 6 month use of any 
cannabis decreased from 74% 
in the 2019 IDRS sample to 
67% in 2020.
Of people who had consumed 
cannabis in the last 6 months, 
97% had smoked it. 
Of those who had consumed
cannabis recently, almost half 
reported daily or more 
frequent use.
Of those who could comment
77% perceived heroin to be 
‘easy’ or ‘very easy’ to obtain, 
down from 89% in 2019.
Of those who could comment
48% perceived crystal 
methamphetamine to be ‘easy’ 
or ‘very easy’ to obtain in 2020.
Past 6 month use of 
non-prescribed oxycodone 
was stable at 15% in the 2019 
IDRS sample to 11% in 2020.
Of those who could comment
81% perceived hydro to be 
‘easy’ or ‘very easy’ to obtain.
63%
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The Illicit Drug Reporting System (IDRS) interviews are conducted 
annually with a sentinel group of people who regularly inject drugs, 
recruited from all capital cities of Australia (N=884 in 2020). The 
results from the IDRS interviews are not representative of all people 
who consume drugs, nor of illicit drug use in the general population, 
but this is not the aim of these data, instead intended to provide 
evidence indicative of emerging issues that warrant further monitoring. 
These findings should be interpreted alongside analyses of other data 
sources for a more complete profile of emerging trends in illicit drug 
use, market features, and harms in Australia.    







The Illicit Drug Reporting System (IDRS) is an ongoing illicit drug monitoring system which has been 
conducted in all states and territories of Australia since 2000, and forms part of Drug Trends. The 
purpose of the IDRS is to provide a coordinated approach to monitoring the use, market features, and 
harms of illicit drugs.  
The IDRS is designed to be sensitive to emerging trends, providing data in a timely manner, rather 
than describing issues in extensive detail. It does this by studying a range of data sources, including 
data from annual interviews with people who regularly inject drugs and from secondary analyses of 
routinely-collected indicator data. This report focuses on the key results from the annual interview 
component of IDRS.  
Methods 
IDRS 2000-2019 
Full details of the methods for the annual interviews are available for download. To briefly summarise, 
participants were recruited using multiple methods (e.g., needle and syringe programs (NSP) and 
peer referral) and needed to: i) be at least 17 years of age (due to ethical requirements); ii) have 
injected at least monthly during the six months preceding interview; and iii) have been a resident for 
at least 12 months in the capital city in which they were interviewed. Interviews took place in varied 
locations negotiated with participants (e.g. treatment services, coffee shops or parks), and were 
conducted using REDCap (Research Electronic Data Capture), a software program to collect data on 
laptops or tablets. Following provision of written informed consent and completion of a structured 
interview, participants were reimbursed $40 cash for their time and expenses incurred.  
In 2019, a total of 902 participants were interviewed during May-July. The sample sizes recruited from 
the capital city in each jurisdiction were: Sydney, NSW n=151; Melbourne, VIC n=148; Adelaide, SA 
n=100; Canberra, ACT n=100; Hobart, TAS n=99; Brisbane and Gold Coast, QLD n=109; Darwin, NT 
n=99; and Perth, WA n=96. 
IDRS 2020: COVID-19 Impacts on Recruitment and Data Collection 
Given the emergence of COVID-19 and the resulting restrictions on travel and people’s movement in 
Australia (which came into effect in March 2020), face-to-face interviews were not possible in most 
jurisdictions due to the risk of infection transmission for both interviewers and participants. For this 
reason, all methods in 2020 were similar to previous years as detailed above, with the exception of: 
1. Means of data collection: Interviews were conducted via telephone across all jurisdictions in 
2020, with some jurisdictions (NT and TAS) also offering face-to-face interviews; 
2. Means of consenting participants: Participants’ consent to participate was collected verbally 
prior to beginning the interview; 
3. Means of reimbursement: Participants were given the option of receiving $40 reimbursement 
via one of three methods, comprising bank transfer, PayID or gift voucher, where completing 
the interview via telephone; 
4. Age eligibility criterion: Changed from 17 years old to 18 years old; and 
5. Additional interview content: The interview was shortened to ease the burden on participants, 
with a particular focus on the impact of COVID-19 and associated restrictions on personal 
circumstances, drug use and physical and mental health. Please refer to Chapter 3 for further 
detail. 






A total of 884 participants were recruited across capital cities nationally (June-September, 2020). The 
sample sizes recruited from the capital city in each jurisdiction were: Sydney, NSW n=155; Melbourne, 
VIC n=179; Adelaide, SA n=100; Canberra, ACT n=100; Hobart, TAS n=74; Brisbane and Gold Coast, 
QLD n=98; Darwin, NT n=78; and Perth, WA n=100. 
Data Analysis  
For normally distributed continuous variables, means and standard deviations (SD) are reported; for 
skewed data (i.e. skewness > ±1 or kurtosis > ±3), medians and interquartile ranges (IQR) are 
reported. Tests of statistical significance have been conducted between estimates for 2019 and 2020. 
Note that no corrections for multiple comparisons have been made and thus comparisons should be 
treated with caution. Values where cell sizes are ≤5 have been suppressed with corresponding 
notation (zero values are reported). References to ‘recent’ use and behaviours refers to the past six-
month time period.  
Interpretation of Findings 
Caveats to interpretation of findings are discussed more completely in the methods for the annual 
interviews but it should be noted that these data are from participants recruited in capital cities, and 
thus do not reflect trends in regional and remote areas. Further, the results are not representative of 
all people who consume illicit drugs, nor of illicit drug use in the general population, but rather are 
intended to provide evidence indicative of emerging issues that warrant further monitoring.  
This report covers a subset of items asked of participants and does not include jurisdictional-level 
results beyond estimates of recent use of various substances, nor does it include implications of 
findings. These findings should be interpreted alongside analyses of other data sources for a more 
complete profile of emerging trends in illicit drug use, market features, and harms in Australia (see 
section on ‘Additional Outputs’ below for details of other outputs providing such profiles). 
COVID-19 
With the intent of consistency, we have kept the report format from previous years to facilitate 
comparison. However, in acknowledgement of the potential impact of COVID-19 and associated 
restrictions, we have provided a comparison of sample demographics in 2019 versus 2020 in Chapter 
2, as well as detailed findings related to impacts of COVID-19 restrictions on drug use and related 
behaviours, markets and harms as reported by participants in Chapter 3.  
Outcomes relating to the previous 12 months reflect behaviours pre and during the COVID-19 
period, whereas those relating to shorter timeframes such as within the previous six months 
or past month may reflect behaviours during or subsequent to stringent restrictions 
depending on the jurisdiction and timeframe. This may mean that some indicators may not be 
sensitive to potential impacts of COVID-19 and associated restrictions. Differences in the 
methodology, and the events of 2020, must be taken into consideration when comparing 2020 
data to previous years, and treated with caution.  
 
For further information on findings related to COVID-19 and associated restrictions, please see earlier 
bulletins released based on IDRS 2020 findings.  
 







Infographics from this report are available for download. There are a range of outputs from the IDRS 
triangulating key results from the annual interviews and other data sources and considering the 
implications of these findings, including jurisdictional reports, bulletins, and other resources available 
via the Drug Trends webpage. This includes results from the Ecstasy and Related Drugs Reporting 
System (EDRS), which focuses on the use of ecstasy and other stimulants. 
Please contact the research team at drugtrends@unsw.edu.au with any queries; to request additional 
analyses using these data; or to discuss the possibility of including items in future interviews. 










Participants were asked questions about select sociodemographic 
characteristics, as well as key drug use characteristics of interest.  






Sample Characteristics  
In 2020, 63% of participants were recruited via NSPs (56% in 2019; p=0.001), followed by word-of-
mouth (25%; 37% in 2019; p<0.001). Sixteen per cent of the 2020 sample had taken part in the 2019 
interview (27% in 2019 had taken part in the 2018 interview; p<0.001).  
In 2020, the national IDRS sample was predominantly male (59%; 68% in 2019; p<0.001) with a mean 
age of 44 (SD=9; Table 1). The majority of the sample (88%) were unemployed at the time of interview 
(88% in 2019; p=0.707), although just over three-fifths (62%; 57% in 2019; p=0.041) of the sample 
reported having received a post-school qualification(s). The vast majority of participants (94%) 
reported receiving a government pension, allowance or benefit in the past month, stable from 2019 
(93%; p=0.562). Participants reported their median weekly income amounted to $500 (IQR=421-555), 
significantly higher than $350 (IQR=275-450; p<0.001) reported by participants in 2019.  
Participants typically reported that heroin was their drug of choice (50%), a significant increase from 
2019 (45%; p=0.018; Figure 1), with heroin being the drug injected most often in the month preceding 
interview, also being a significant increase from 2019 (46%; 40% in 2019; p=0.013; Figure 2).  
In addition, there was an increase of participants reporting heroin consumption on a weekly or more 
frequent basis in 2020 compared to 2019 (51%; 43% in 2019; p=0.001; Figure 3). Significantly fewer 
participants reported weekly or more frequent use of cannabis in 2020 compared to 2019 (51%; 57% 
in 2019; p=0.013; Figure 3). 
 
Table 1: Demographic characteristics of the sample, nationally and by jurisdiction, 2019-2020 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=902 N=884 N=155 N=100 N=179 N=74 N=100 N=100 N=78 N=98 




(10) 44 (9) 44 (9) 44 (9) 44 (8) 43 (8)  46 (9) 43 (10) 44 (11) 45 (10) 
% Male 68 59*** 61 55 59 58 50 67 63 58 
% Aboriginal and/or 
Torres Strait Islander 22 18 26 18 9 15 15 20 39 12 
% Sexual identity           
Heterosexual 87 86 83 79 88 84 86 87 93 87 
Homosexual 3 4 8 - 4 - - - 0 - 
Bisexual 8 8 8 14 7 10 9 - - 9 
Queer 1 1 - 0 - - 0 - 0 0 
Other 1 1 - - 0 0 - - 0 - 





12) 10  10 10 10 10 11 10 10 
% Post-school 
qualification(s)^ 57 62* 61 67 58 65 67 59 46 74 
% Current employment 
status           
Unemployed 88 88 92 85 92 89 89 90 90 76 
Full time work 1 3 - - - - - - - 10 
% Past month gov’t 
pension, allowance or 
benefit  
93 94 95 96 97 95 97 92 96 85 






 National NSW ACT VIC TAS SA WA NT QLD 
 N=902 N=884 N=155 N=100 N=179 N=74 N=100 N=100 N=78 N=98 
 2019 2020         
Current median 




































accommodation           
Own home (inc.renting)~ 70 69 73 83 59 65 74 64 68 71 
Parents’/family home 6 6 - - 5 - 10 12 - - 
Boarding house/hostel 6 9 8 - 18 - 9 9 - 8 
Shelter/refuge 2 2 - - - - 0 - 0 - 
No fixed address 15 12 13 9 12 16 6 13 19 13 
Other 1 1 - - - 0 - 0 - 0 
Note. ̂ Includes trade/technical and university qualifications. ~ Up until and including 2019, ‘own home’ included private rental and public 
housing. In 2020, these were separated out. In 2020, ‘students’ comprised participants who were currently studying for either 
‘trade/technical’ or ‘university/college’ qualifications. - Values suppressed due to small cell size (n≤5 but not 0). / denotes that this item was 
not asked in these years. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020 for the national sample. 
 
Figure 1: Drug of choice, nationally, 2000-2020 
 
 
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent 
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Figure 2: Drug injected most often in the past month, nationally, 2000-2020 
 
 
Note. Participants could only endorse one substance. Substances listed in this figure are the primary endorsed; a nominal per cent 
endorsed other substances. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Figure 3: Weekly or more frequent substance use in the past six months, nationally, 2000-2020 
 
 
Note. Computed of the entire sample regardless of whether they had used the substance in the past six months. Y axis reduced to 80% 
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Participants were asked various questions regarding their experience 
during COVID-19 and the impacts the virus had on their lives following 
implementation of restrictions in Australia at the beginning of March, 
2020. 







The first COVID-19 diagnosis occurred in Australia on 25 January 2020, with a rapid increase in cases 
throughout March (peak 469 cases 28 March 2020), declining subsequently (<20 cases per day) until 
a resurgence from late June, largely based in Victoria and to a lesser extent in New South Wales 
(Figure 4). As a nation of federated states and territories, public health policy including restrictions on 
movement and gathering varied by jurisdiction, however restrictions on gatherings were implemented 
across jurisdictions from early March; by the end of March, Australians could only leave their 
residence for essential reasons. These restrictions were reduced from mid-June, again with variation 
across jurisdictions. Notably, significant restrictions were enforced again in Victoria (from July), 
whereby Stage 4 restrictions were implemented in early August 2020. 
Figure 4: Timeline of COVID-19 in Australia and IDRS data collection period, 2020 
 
Note. Data obtained from https://www.covid19data.com.au/. 
Methods 
IDRS interviews commenced on 23 June and concluded on 11 September 2020.  
In 2020, the IDRS interview was condensed to alleviate the burden on participants completing the 
survey via telephone, and a particular focus on COVID-19 was present throughout the interview in 
order to capture changes in drug purchasing, use and harm reduction behaviours. 
Questions pertaining to the impacts of COVID-19 on lifestyle such as housing situation and changes 
in employment, amongst others, were examined, as well as COVID-19 specific questions such as 
symptoms, testing, diagnosis, social distancing and isolation or quarantine practices. 
Furthermore, so as to ensure more complete capture of changes brought about by COVID-19, 
questions were posed throughout the interview to explore demographic characteristics, drug 
consumption, injecting practices and harm reduction behaviours which occurred in February 2020 as 






compared to March, when COVID-19 restrictions on travel and people’s movement in Australia were 
introduced.   
A brief description of methods can be found in the Background section of this document. 
COVID-19 Testing and Diagnosis 
One-fifth (20%) of the IDRS sample had been tested for SARS-COV-2 by the time of interview, and 
no participants had been diagnosed with the virus. When asked how worried participants currently 
were of contracting COVID-19, 23% responded ‘slightly’, 15% said ‘moderately’, 7% said ‘very’ and 
4% said ‘extremely’.  
Social and Financial Impacts of COVID-19 Restrictions 
COVID-19 related health behaviours. Since the beginning of March 2020, 89% of participants had 
practiced social distancing (i.e., avoiding public transport and social gatherings) and 70% had 
undergone home isolation, whereby participants were only able to leave home for ‘essential’ reasons, 
such as to go to work, exercise or collect groceries. One per cent reported that they were required to 
quarantine for 14 days due to being at risk of contracting COVID-19.  
Participants were asked about various health precautions they had engaged in in the four weeks prior 
to interview (Figure 5). Most commonly, participants reported using hand sanitiser/ washing hands 
more frequently (80%), keeping distance from people (73%) and avoiding public spaces and events 
(46%).  
Furthermore, participants reported a number of concerns related to the COVID-19 pandemic; 
concerns most commonly reported comprised the increased cost of drugs (60%), limited availability 
of drugs (60%) and family or loved ones getting sick or dying (56%) (Figure 6). 
Figure 5: Health precautions related to COVID-19 in the past four weeks, nationally,  2020 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 
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Figure 6: Participant concerns relating to the COVID-19 pandemic, nationally, 2020 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 but 
not 0).  
Housing. Almost one-fifth (18%) of participants reported that their living situation had changed since 
the beginning of March (n=158). As to why participants’ living situation had changed, reasons included 
rent increase (8%), move unrelated to COVID-19 (8%) and participant was given a new shelter/short 
term housing or put up in a hotel (8%).  
Employment and Income. When asked about their income in the four weeks prior to interview as 
compared to how much participants received in the month of February 2020, 44% of participants 
reported that they were receiving more income, 8% reported less income, and 48% reported a similar 
amount of income (Table 2). 
Nearly two-thirds of participants (63%) reported experiencing any financial difficulty during the past 
month; most commonly reported difficulties were being unable to buy food (38%) and unable to pay 
household or phone bills on time (31%). Furthermore, one-third (34%) of the sample reported asking 
for financial help from friends or family, and 28% of participants asked for help from 
welfare/community organisations (Table 2). It should be noted that no data were collected on financial 
difficulties prior to COVID-19, and thus these difficulties cannot be linked solely to impacts of COVID-
19 and associated restrictions.    
Table 2: Social and financial impacts of COVID-19 restrictions, nationally, 2020 
 National 2020 
 N=884 
% Change in total income in the past month compared to February  
More money 44 
Less money 8 
About the same 48 
% Financial difficulties in the past month#  
Could not pay household or phone bills on time 31 
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Requested deferred payment of mortgage/rent/loan 6 
Unable to buy food or went without meals 38 
Unable to heat/air-condition house 13 
Asked for financial help from friends or family 34 
Asked for help from welfare or community organisations 28 
Difficulty paying for medicines 20 
Difficulty paying for medical treatment 11 
Note. The response ‘Don’t know’ was excluded from analysis.  # participants could endorse multiple responses. - Per cent suppressed 
due to small cell size (n≤5 but not 0). 
 
Drug Use 
Main drug injected. Twelve per cent of participants reported that the drug injected most often in the 
past month was not the same as the drug injected most often in February 2020. Of these participants 
(n=107), the main transitions cited were from methamphetamine to heroin (22%) and heroin to 
methamphetamine (17%). In addition, 9% reported to have started to inject methamphetamine in the 
past month compared to not injecting methamphetamine in February (Table 3).  
Frequency of drug injection. Thirty-six per cent of participants reported injecting drugs at a different 
frequency in the past month as compared to February 2020; 25% reported greater frequency of 
injection, and 11% reported lesser frequency (Table 3). 
Table 3: Drug injected most often in February (pre-COVID-19 restrictions) as compared to the past month 
(during COVID-19 restrictions), nationally, 2020 
 National 2020 
 February Past month 
% Drug injected most often in that month   
Heroin 46 46 
Morphine 5 5 
Methamphetamine 42 41 
Oxycodone - - 
Methadone 2 2 
Buprenorphine-naloxone  1 1 
% reporting change in drug injected most often from 
February to past month^ 12  
% Frequency of drug injection in that month   
Not in the last month  2 2 
Weekly or less 13 19 
More than weekly, not daily  31 32 
Once a day  21 17 
2 to 3 times a day  22 22 
More than 3 times a day  11 9 
% reporting decrease in frequency Overall: 25  
% reporting increase in frequency Overall: 11  
% reporting stable frequency Overall: 64  
Note. The response ‘Don’t know’ was excluded from analysis. - Per cent suppressed due to small cell size (n≤5 but not 0).  
 






Perceived changes in drug use. In the 2020 interviews, additional questions were asked of 
participants who reported past six-month use of various drugs about changes in their use of that drug 
since the beginning of March 2020 (since COVID-19 restrictions) as compared to before (Figure 7). 
Further detail on trends in drug use and consumption patterns can be found in subsequent chapters.  
For the most part, participants reported no change in use of the various assessed drugs. Between 
one-fifth and half of participants reported a perceived decrease (i.e., decline or cessation) in use of 
methamphetamine (48%), heroin (36%), and cocaine (22%).  One-quarter reported an increase in 
use for alcohol (27%) and cannabis (25%).  
The primary reasons cited for decreasing use of methamphetamine and heroin were ‘decreased 
availability’ of the drug (57% and 46%, respectively). Other commonly endorsed reasons were ‘drug 
is more expensive’ and ‘worried about the effects on my physical health’. ‘Boredom’ was the primary 
reason why participants increased their use of alcohol and cannabis (33% and 39%, respectively). 
Other commonly endorsed reasons were ‘greater depression/anxiety with COVID-19’ and ‘more time 
to use the drug’.  
Figure 7: Perceived change in drug use since March 2020 (since COVID-19 restrictions) as compared to 
before, nationally, 2020 
 
Note. Change in use items were asked of participants who reported use in the past six months. The response ‘Don’t know’ was excluded 
from analysis.  Estimates reflect reports on non-prescribed use for pharmaceutical medicines.  
 
Perceived changes in frequency of drug injection. Participants who reported past six-month 
injection of pharmaceutical opioids were asked about changes in frequency of injection since the 
beginning of March 2020, as compared to before (Figure 8).  
Approximately one-quarter of participants reported a decrease in injection of morphine (27%), fentanyl 
(26%) and methadone syrup (25%). One-third reported an increase in injection for buprenorphine-
naloxone (33%).  
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Figure 8: Perceived change in injecting frequency of pharmaceutical opioids since March 2020 (since 
COVID-19 restrictions) as compared to before, nationally, 2020 
 
Note. These items were asked of participants who reported injecting the drug in the past six months.The response ‘Don’t know’ was excluded 
from analysis.  Estimates reflect reports of any (prescribed and/or non-prescribed) injection for pharmaceutical opioids.  
 
Price, Perceived Purity and Availability  
Participants were asked to answer a number of questions regarding the price, perceived purity and 
availability of various drugs, providing they were confident in their knowledge of the drug in question. 
Further details on trends over time in these indicators can be found in the subsequent chapters.  
Additional questions were included in the 2020 interview for each of the main substances specifically 
assessing perceived change in price, perceived purity and availability since March 2020 (since 
COVID-19 restrictions) as compared to before.  
Crystal methamphetamine and heroin were the most commonly reported illicit drugs to have increased 
in price since the beginning of March 2020 as compared to before (91% and 62%, respectively). The 
price of hydroponic cannabis and bush cannabis was most commonly reported as stable (78% and 
79%, respectively) (Figure 9). Fifty-nine per cent of participants perceived the purity of crystal 
methamphetamine to have decreased since the beginning of March 2020, as compared to before 
(Figure 10). Crystal methamphetamine and morphine were most commonly cited as illicit drugs which 
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Figure 9: Change in price of select illicit drugs since March 2020 (since COVID-19 restrictions) as 
compared to before, nationally, 2020 
 
Note. Among those who commented. The response ‘Don’t know’ was excluded from analysis.  
Figure 10: Change in perceived purity of heroin and crystal methamphetamine since March 2020 (since 
COVID-19 restrictions) as compared to before, nationally, 2020 
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Figure 11: Change in perceived availability of select illicit drugs since March 2020 (since COVID-19 
restrictions) as compared to before, nationally, 2020 
 
 
Note. Among those who commented. The response ‘Don’t know’ was excluded from analysis.  
 
Risk and Protective Behaviours 
Drug Treatment. Of those participants who were in treatment in the six months preceding interview, 
5% were receiving drug treatment before March, 7% said since March and 43% said both before and 
since March. Of this group, almost half (49%) reported any disruption to treatment since March 2020 
(since COVID-19 restrictions), namely appointments moving to phone/video rather than face-to-face 
(34%), changed hours of service (17%), and treatment service closed (8%).  
Of those in treatment at the time of interview (n=421), 81% reported that their treatment satisfaction 
was similar since March 2020 (since COVID-19 restrictions); 9% ‘better’, and 10% ‘lower’.  
Furthermore, for those on opioid agonist treatment (OAT) since March (n=373), 25% reported an 
increase in take-away doses, whilst 75% reported no change in their dose of medication. Forty-two 
per cent of participants reported that urine testing/breathalysing and frequency of pharmacy doses 
remained mostly stable (Figure 12). Twenty-three per cent of participants on OAT in the last six 
months reported having missed a dose of medication (e.g. methadone, buprenorphine, 
buprenorphine-naloxone or buprenorphine depot injection) due to service disruptions (e.g. service 
was closed or changed hours of service). Those on OAT since March were also asked to what degree 
they felt involved in decision-making around changes to their treatment since the beginning of March 
(since COVID-19 restrictions); the larger per cent of those who commented responded ‘they 
experienced no changes to their treatment’ (34%), followed by 17% that reported ‘extremely’ and 17% 
reported ‘very’. 
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Figure 12: Changes in aspects of drug treatment since March 2020, as compared to before amongst 
participants reporting recent opioid agonist treatment, nationally, 2020 
 
Note. Among those who had received OAT since March and who commented. The response ‘Don’t know’ was excluded from analysis.  
Injecting equipment access and disposal. Over one-tenth of participants (12%) reported having 
experienced trouble in obtaining new sterile needles and syringes since the beginning of March (since 
COVID-19 restrictions). Of those who had trouble obtaining new sterile needles and syringes and 
commented (n=103), 50% of participants reported having re-used their own needles more than they 
normally would.  
Five per cent of the sample reported difficulties in safely disposing of used needles and syringes in a 
sharps bin since March (since COVID-19 restrictions). The most commonly reported reasons for this 
comprised ‘service was closed’ and ‘COVID-19 restrictions meant I could not travel to the service’ 
(20% each of those reporting difficulties).   
Injecting practices. The majority of participants reported ‘no change’ when reporting changes in their 
injecting practices since March 2020 (since COVID-19 restrictions) with regards to borrowing and 
lending needles. However, 9% reported an increase in re-using their own needles (Figure 13)  and 
13% reported injecting alone more. Few (2%) reported an increase in needle sharing (receptive or 
distributive). 
Mental health. When asked to rate their mental health in the past four weeks as compared to how 
they were feeling in the month of February (before COVID-19 restrictions), 32% of participants rated 
their mental health as being ’worse’, 50% reported ’similar’ and 18% reported their mental health as 
‘better’.  
Physical health. When asked to rate their physical health in the past four weeks as compared to how 
they were feeling in the month of February (before COVID-19 restrictions), 51% said ‘similar’, 23% 
said ‘worse’ and 15% said ‘better’. 
Behaviours to protect against COVID-19 transmission or impacts of restrictions. Over one-
quarter (28%) of participants reportedly sought information on how to reduce the risk of acquiring 
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COVID-19 or avoiding impacts of restrictions on drug acquisition and use. The most common sources 
cited comprised a harm reduction service (11%) and GP (6%).  
The majority (82%) of participants reported engaging in various harm reduction behaviours to reduce 
the risk of acquiring COVID-19 or impacts of COVID-19 restrictions while using or obtaining drugs 
(Table 4).  
Figure 13: Change in frequency of injecting practices since March 2020 (since COVID-19 restrictions) as 
compared to before, nationally, 2020 
 
Note. Among those who commented. The response ‘Don’t know’ was excluded from analysis.  
 
Table 4: Harm reduction behaviours to reduce risk of COVID-19 transmission and/or impacts of restrictions, 
nationally, 2020 
 National 2020 
 N=884 
Washed hands with soap/sanitiser before handling drugs or money 67 
Avoided sharing needles/syringes with other people 56 
Prepared drugs yourself 47 
Avoiding sharing other drug use equipment with other people 42 
Stocked up on sterile needles/syringes 40 
Wiped down drug packages/wraps with soap/sanitiser 28 
Stocked up on other sterile drug use equipment 23 
Obtained take-home naloxone/narcan 17 
Stocked up on illicit/non prescribed drugs 16 
Avoided smoking/vaping drugs 12 
Stocked up on prescription medicines prescribed to you 8 
Note. - Per cent suppressed due to small cell size (n≤5 but not 0). Participants could endorse multiple responses.  
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Participants were asked about their recent (past six month) use of 
heroin and of homebake heroin. Participants typically describe heroin 
as white/off-white rock, brown/beige rock or white/off-white powder. 
Homebake is a form of heroin made from pharmaceutical products and 
involves the extraction of diamorphine from pharmaceutical opioids 
such as codeine and morphine.   






Patterns of Consumption 
Recent Use (past 6 months) 
Recent use of any heroin has remained relatively stable over the years, with between half and two-
thirds of the sample reporting use. The per cent reporting recent use increased from 2019 (55%) to 
2020 (63%; p=0.001; Figure 14). It is important to note marked differences across jurisdictions, 
ranging from less than one in twenty participants reporting recent use in the NT samples, to more 
than eight in ten participants reporting recent use in the ACT and VIC samples in 2020 (Table 5). SA 
recorded the greatest increase in 2020 relative to 2019 (47% versus 28%, respectively; p=0.009), 
whereas the other jurisdictions remained stable (Table 5).  
Frequency of Use 
Median frequency of use nationally has typically been equivalent to four days a week in the past six 
months (2020: median 96 days, IQR=30-180), stable from 2019 (90 days, IQR=24-180; p=0.345) 
(Figure 14). In 2020, just over one-third (36%) of participants who had recently used heroin reported 
daily use (36% in 2019; p=0.901), and 80% reported weekly use, stable from 78% in 2019 (p=0.277). 
No one reported daily use in the NT and TAS sample, whereas the ACT, NSW and the VIC samples 
had the highest per cent (45%, 44% and 43%, respectively).  
Routes of Administration 
Injecting remained the most common route of administration among people who consumed heroin, 
with 100% reporting injecting heroin in 2020 (99% in 2019; p=0.194). Participants who reported 
injecting did so on a median of 96 days (IQR=30-180) which remained stable from 2019 (90 days; 
IQR=24-180; p=0.392). Few participants reported smoking (7%; 7% in 2019; p=0.876), swallowing 
(2%; 1% in 2019; p=0.981) and snorting (1%; 1% in 2019; p=0.439) heroin.   
Quantity 
The median amount of heroin used per day in the last six months was 0.20 grams (IQR=0.10-0.50; 
0.20 grams in 2019; IQR=0.10-0.40; p=0.263). 
Figure 14: Past six month use and frequency of use of heroin, nationally, 2000-2020 
 
  
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
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Table 5: Past six month use of heroin, by jurisdiction, 2000–2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 95 92 97 38 73 80 56 86 
2001 96 83 90 24 65 55 36 62 
2002 96 89 94 21 48 64 22 81 
2003 97 88 90 26 55 63 16 64 
2004 95 91 86 19 60 69 34 79 
2005 88 86 89 19 61 69 24 64 
2006 81 71 76 9 60 53 12 63 
2007 88 72 85 - 67 57 7 65 
2008 83 86 85 - 51 59 14 74 
2009 94 78 79 12 72 71 13 75 
2010 92 78 85 8 64 69 5 81 
2011 87 79 81 19 57 79 9 65 
2012 89 74 84 9 52 80 11 65 
2013 83 75 83 10 41 75 17 72 
2014 85 75 83 13 43 79 7 66 
2015 91 79 74 - 49 75 14 50 
2016 86 70 77 7 37 78 7 58 
2017 80 74 80 15 52 66 13 55 
2018 83 75 83 8 35 67 9 45 
2019 82 77 85 15 28 62 - 63 
2020 78 85 86 24 47** 69 - 64 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Price, Perceived Purity and Availability 
Price 
In 2020, the reported median price last paid for one gram of heroin nationally was $400 (IQR=250-
550; n=95), similar to 2019 ($350; IQR=250-400; n=;65 p=0.063). Participants reported a median last 
price of $50 per cap in 2020 (IQR=50-100; n=25), with a median price of ($50; IQR=50-50; n=79) 
recorded in 2019 (p=0.021) (Figure 15). Furthermore, participants reported a median price of $70 per 
point (IQR=50-100; n=259), a significant increase from $50 in 2019 (IQR=50-75; n=221; p<0.001).   
Perceived Purity 
Among those who were able to comment (n=485), approximately two in five participants perceived 
the current purity of heroin to be ‘low’ (44%), a significant increase relative to 2019 (27%; p<0.001). 
A further 14% perceived the purity of heroin to be ‘high’, a significant decrease from 25% in 2019 
(p<0.001), whereas one-quarter (25%) perceived purity to be ‘medium’ (31% in 2019; p=0.033) 
(Figure 16).  
Perceived Availability 
Of those who were able to comment (n=496), 42% perceived the current availability of heroin as being 
‘easy’ to obtain relative to 34% in 2019 (p=0.020). A further 35% perceived heroin as being ‘very easy’ 
to obtain, as compared to 54% in 2019 (p<0.001). In contrast, 19% perceived heroin as being ‘difficult’ 










Figure 15: Median price of heroin per cap and gram, nationally, 2000-2020 
 
 
Note. Among those who commented. Price for a gram of heroin was not collected in 2000. The error bars represents the IQR. *p<0.050; 
**p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Figure 16: Current perceived purity of heroin, nationally, 2000-2020 
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Figure 17: Current perceived availability of heroin, nationally, 2000-2020 
 
 










53 52 48 51 47 50 49









37 34 38 36 38
39 39




14 11 11 12
21
12 14 9 11 11 11 13



























Very easy Easy Difficult Very difficult


















Participants were asked about their recent (past six month) use of 
various forms of methamphetamine, including powder (white particles, 
described as speed), base (wet, oily powder) and crystal (clear, ice-
like crystals). 






Patterns of Consumption (any methamphetamine) 
Recent Use (past 6 months) 
Recent use of any methamphetamine (powder, base and crystal) peaked in 2003 (89%), before 
declining to 60% in 2010, with a subsequent rise in the years following. Nevertheless, a significant 
decline transpired in 2020 (72%) relative to 2019 (78%; p=0.006) (Figure 18). Across the jurisdictions, 
at least three in five participants reported recent use of methamphetamine in 2020, ranging from 63% 
in the QLD sample to 83% in the NT sample, with a significant decrease in the per cent reporting use 
from 2019 to 2020 observed in the ACT sample (79% versus 65%, respectively; p=0.032) (Table 6).   
Frequency of Use 
In 2020, frequency of use remained largely stable at a median of 48 days (IQR=12-108; 48 days in 
2019; IQR=12-97; p=0.568) (Figure 19). The per cent of participants who had recently used 
methamphetamine reporting weekly or more frequent use also remained stable compared to 2019 
(68% versus 66% in 2019; p=0.674).  
Forms of Methamphetamine 
There has been a shift over time to decreasing use of methamphetamine powder and base forms and 
increasing use of crystal methamphetamine (Figure 18). Indeed, of those who had used 
methamphetamine in the six months preceding interview in 2020 (n=639), most participants had used 
crystal methamphetamine (71%; 75% in 2019), followed by powder (20%; 23% in 2019).  
Figure 18: Past six month use of any methamphetamine and of methamphetamine powder, base, and 
crystal, nationally, 2000-2020 
 
 
Note. #Base asked separately from 2001 onwards. ‘Any methamphetamine’ includes crystal, powder, base and liquid methamphetamine 
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Note. Frequency of use data was not collected in 2020 for base methamphetamine. Median days computed among those who reported 
recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 90 days to improve visibility of 
trends. Median days used base and crystal not collected in 2000-2001. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Table 6: Past six month use of any methamphetamine, by jurisdiction, 2000–2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 40 68 53 83 52 85 74 71 
2001 51 82 76 85 81 92 70 83 
2002 48 70 73 84 85 85 72 81 
2003 53 71 79 88 72 90 71 89 
2004 56 81 71 91 71 85 70 81 
2005 58 73 79 95 78 75 72 78 
2006 72 92 81 83 78 86 64 82 
2007 62 83 74 88 74 70 68 78 
2008 74 74 68 74 69 74 57 59 
2009 57 75 70 80 61 63 55 70 
2010 57 59 60 70 74 64 36 59 
2011 60 73 65 77 66 64 55 71 
2012 72 77 67 77 79 72 48 53 
2013 75 66 61 74 75 72 43 58 
2014 75 76 77 70 75 66 37 72 
2015 66 81 74 72 76 71 67 67 
2016 77 83 73 75 77 65 71 70 
2017 69 80 66 69 76 70 66 74 
2018 76 85 78 79 83 67 75 72 
2019 76 79 70 81 90 79 90 68 
2020 77 65* 66 77 81 73 83 63 
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Patterns of Consumption (by form) 
Methamphetamine Powder   
Recent Use (past 6 months): Nationally, use 
of powder methamphetamine has generally 
been decreasing over time but stabilised from 
2016, with approximately one in five 
participants reporting recent use since (20% in 
2020; 23% in 2019; p=0.144) (Figure 18). Most 
jurisdictions have reflected this trend, with 
some fluctuation over time. ACT recorded a 
significant decrease from 27% in 2019 to 13% 
in 2020 (p=0.020) (Table 7).  
Frequency of Use: Nationally, frequency of 
use remained stable in 2020 at a median of 12 
days (IQR=3-60; 10 days in 2019; IQR=3-48; 
p=0.369) (Figure 19). In 2020, over two-fifths 
(43%) of participants who had recently used 
powder methamphetamine reported weekly or 
more frequent use, stable from 38% in 2019 
(p=0.380).  
Routes of Administration: Most consumers 
(93%) reported recent injection of powder (94% 
in 2019; p=0.689) and reported doing so on a 
median of 12 days (IQR=3-71), stable relative 
to 2019 (10 days; IQR=3-48 p=0.393). One-
fifth (21%) reported smoking powder, stable 
relative to 2019 (24%; p=0.607).  
Quantity: Of those who reported recent use 
and responded (n=156), the median amount of 
powder used on a typical day in the past six 
months was 0.20 grams (IQR=0.10-0.40) (0.20 
grams in 2019; IQR=0.10-0.30; p=0.233). 
Methamphetamine Base 
Recent Use (past 6 months): Base has 
typically been the least commonly used form of 
methamphetamine since monitoring 
commenced in 2001. Approximately one in ten 
participants have reported recent use of base 
each year since 2013, with 8% reporting recent 
use in 2020 (9% in 2019; p=0.512) (Figure 18). 
No significant difference was observed 
between 2019 and 2020 at the jurisdictional 
level.  
Frequency of Use: Data for frequency of use 
for base methamphetamine was not collected 
in 2020. For further information, please refer to 
the 2019 IDRS National Report. 
Routes of Administration: Most recent 
consumers of base reported injecting the form 
(97%; 95% in 2019; due to small numbers 
reporting recent use, significance testing for 
routes of administration were not undertaken), 
with few participants reporting smoking (n≤5).  
Quantity: Data on the quantity of base recently 
used was not collected in 2020. For further 
information, please refer to the 2019 IDRS 
National Report. 
Methamphetamine Crystal 
Recent Use (past 6 months): Reports of 
recent use of crystal methamphetamine have 
been increasing since 2009 (Figure 18), 
surpassing powder methamphetamine from 
2012 onwards and peaking at 75% in 2019, 
though a significant decrease was observed in 
2020 (71%; p=0.035). At the jurisdictional level, 
recent use ranged from 63% in the QLD and 
ACT sample, respectively, to 83% in the NT 
sample in 2020 (Table 9).  
Frequency of Use: Frequency of use 
remained stable in 2020, with participants 
reporting use on a median of 48 days (IQR=12-
100; 48 days in 2019; IQR=10-96; p=0.542) in 
the past six months (Figure 19). In 2020, two-
thirds (66%) of recent consumers reported 
using methamphetamine crystal on a weekly or 
more frequent basis, stable from 64% in 2019 
(p=0.390), with a further 16% reporting daily 
use (17% in 2019; p=0.689).  
Routes of Administration: The main route of 
administration was injecting (95%; 97% in 
2019; p=0.033), followed by smoking (35%; 
39% in 2019; p=0.264). Participants who 
reported injecting did so on a median of 45 
days (IQR=12-96), stable from 2019 (42 days; 
IQR=10-96; p=0.266). The per cent of 
participants who had recently used crystal who 
reported recent smoking ranged between 9% 
in the NT sample and 45% in the WA sample. 






Quantity: Of those who reported recent use 
and responded (n=596), the median amount of 
crystal used on an average day of consumption 
in the past six months was 0.10 grams 
(IQR=0.10-0.20; 0.20 grams in 2019; 
IQR=0.10-0.30; p=0.059).
 
Table 7: Past six month use of powder methamphetamine, by jurisdiction, 2000-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 32 63 49 77 51 81 70 58 
2001 42 63 74 45 47 87 63 80 
2002 39 51 70 35 56 77 67 55 
2003 31 48 70 51 53 71 60 58 
2004 35 41 65 60 44 61 60 61 
2005 38 59 75 76 39 61 69 65 
2006 49 58 71 54 39 66 57 54 
2007 35 55 65 63 42 61 58 62 
2008 38 37 64 61 34 61 50 35 
2009 33 46 65 56 33 54 50 46 
2010 29 48 53 56 29 51 25 41 
2011 30 46 49 67 36 43 43 40 
2012 17 42 39 70 34 45 46 30 
2013 14 29 23 61 40 48 31 37 
2014 17 36 25 50 34 39 16 31 
2015 13 15 18 49 32 34 25 27 
2016 17 18 9 33 19 18 24 27 
2017 10 20 15 30 18 16 19 34 
2018 11 23 16 22 31 12 17 34 
2019 13 27 11 35 44 26 15 20 
2020 11 13* 10 43 35 36 - 19 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020.
  







Table 8: Past six month use of base methamphetamine, by jurisdiction, 2001-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2001 23 36 32 52 59 56 18 75 
2002 23 30 20 74 65 56 21 42 
2003 32 13 18 46 51 40 30 50 
2004 31 25 11 72 46 45 26 60 
2005 38 28 13 79 61 54 16 40 
2006 43 32 15 55 52 37 25 53 
2007 41 32 8 48 42 22 20 48 
2008 33 18 5 25 37 13 10 34 
2009 36 21 13 55 31 12 16 41 
2010 29 18 3 40 43 8 6 30 
2011 17 17 11 39 35 6 12 37 
2012 15 15 11 43 32 6 7 21 
2013 12 6 3 17 31 11 7 22 
2014 12 - 3 19 30 8 - 22 
2015 6 10 4 9 26 - - 20 
2016 11 5 0 - 24 - 6 14 
2017 8 11 3 - 30 7 7 20 
2018 9 8 - - 8 - 10 14 
2019 8 8 - - 24 - - 16 
2020 4 - - 8 28 8 - 10 
Note. Base asked separately from 2001 onwards. - Values suppressed due to small cell size (n≤5 but not 0).  *p<0.050; **p<0.010; 
***p<0.001 for 2019 versus 2020. 
 
Table 9: Past six month use of crystal methamphetamine, by jurisdiction, 2000-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 14 17 9 6 11 51 6 13 
2001 29 72 52 56 58 85 24 75 
2002 25 34 26 20 56 74 20 39 
2003 38 65 50 69 48 80 34 60 
2004 45 73 41 52 48 83 32 51 
2005 38 62 29 50 46 68 21 36 
2006 57 88 53 56 49 76 29 55 
2007 50 80 43 38 41 56 29 39 
2008 69 68 39 32 49 61 28 40 
2009 46 57 32 26 30 43 15 46 
2010 48 48 36 20 60 40 18 37 
2011 53 57 53 26 44 46 28 50 
2012 68 66 59 43 56 64 26 44 
2013 74 61 55 45 57 59 30 50 
2014 74 72 75 54 60 53 26 58 
2015 65 79 71 59 70 64 60 62 
2016 77 78 73 73 73 75 62 69 
2017 69 79 63 65 72 69 60 69 
2018 76 85 77 76 79 64 74 70 
2019 74 77 68 76 89 75 87 65 
2020 75 63 64 77 80 69 83 63 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
  






Price, Perceived Purity and 
Availability 
Methamphetamine Powder  
Questions pertaining to the price, perceived 
purity and availability of methamphetamine 
powder were not asked of participants in 2020. 
For further information, please refer to the 2019 
IDRS National Report.  
Methamphetamine Base  
Questions pertaining to the price, perceived 
purity and availability of methamphetamine 
base were not asked of participants in 2020. 
For further information, please refer to the 2019 
IDRS National Report.  
Methamphetamine Crystal  
Price: The median price for a point of crystal 
increased significantly in 2020 ($100; IQR=60-
150; n=435; $50 in 2019; IQR=50-50; n=455; 
p<0.001). Across the years, the median price 
of a gram of crystal has ranged between $250 
and $600, with the median price recorded in 
2020 being the second highest recorded price 
since monitoring commenced ($500; IQR=363-
700; n=51), and a significant increase from 
$250 in 2019 (IQR=200-300; n=88; p<0.001) 
(Figure 20).  
Perceived Purity: Among those that were able 
to comment (n=536), 14% perceived the purity 
of crystal to be ‘high’, a significant decrease 
relative to 2019 (35%; p<0.001). On the 
contrary, two-fifths (40$) perceived purity to be 
‘low’, a significant increase from 16% reporting 
‘low’ purity in 2019 (p<0.001) (Figure 21). 
Perceived Availability: Of those who were 
able to comment (n=553), one-third (33%) 
reported that crystal was ‘difficult’ to obtain, a 
significant increase relative to 2019 (5%; 
p<0.001). Significantly less participants 
reported that crystal was ‘very easy’ to obtain 




















Figure 20: Median price of methamphetamine crystal per point and gram, nationally, 2001-2020 
 
 
Note. Among those who commented. No data available for gram in 2001. The error bars represents the IQR. *p<0.050; **p<0.010; 
***p<0.001 for 2019 versus 2020. 
 
Figure 21: Current perceive purity of crystal methamphetamine, nationally, 2002-2020 
 
 
Note. Methamphetamine asked separately for the three different forms from 2002 onwards. The response ‘Don’t know’ was excluded 
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Figure 22: Current perceived availability of crystal methamphetamine, nationally, 2002-2020 
 
  
Note. Methamphetamine asked separately for the three different forms from 2002 onwards. The response ‘Don’t know’ was excluded 




























































Very easy Easy Difficult Very Difficult















Participants were asked about their recent (past six month) use of 
various forms of cocaine. Cocaine hydrochloride, a salt derived from 
the coca plant, is the most common form of cocaine available in 
Australia. ‘Crack’ cocaine is a form of freebase cocaine (hydrochloride 
removed), which is particularly pure. ‘Crack’ is most prevalent in North 
America and infrequently encountered in Australia. 






Patterns of Consumption 
Recent Use (past 6 months) 
The per cent reporting recent use of cocaine has decreased over the period of monitoring. In saying 
this, a significant increase in recent use was observed in 2020 relative to 2019 (17%; 13% in 2019; 
p=0.006) (Figure 23). The per cent reporting use in 2020 varied across the jurisdictions, ranging from 
five or less participants in the NT sample to 23% of the NSW sample. Overall, the per cent has 
remained relatively stable in each of the jurisdictions over time except for a substantial decrease in 
cocaine use in NSW (Table 10).  
Frequency of Use 
Median frequency of use at the national level has varied between two and eight days, with a median 
of three days (IQR=1-6; n=153) observed in 2020, stable from 2019 (3 days; IQR=1-6; p=0.286) 
(Figure 23). Of those who had recently used cocaine and commented (n=153), almost one-tenth (8%) 
reported weekly or more frequent use, consistent with 2019 (11%; p=0.726).  
Routes of Administration 
No statistically significant changes in route of administration were observed between 2019 and 2020; 
snorting proved to be the most common route amongst those reporting recent use (55%; 56% in 2019; 
p=0.976), followed by injecting (52%; 63% in 2019; p=0.081). A smaller per cent reported smoking 
(7%; 8% in 2019; p=0.819) and swallowing cocaine (4%; 7% in 2019; p=0.279). 
Quantity 
Of those who reported recent use and responded (n=133), the median amount of cocaine used on an 
average day of consumption in the six months preceding interview was 0.30 grams (IQR=0.10-0.50; 
0.30 grams in 2019; IQR=0.10-1.00; p=0.217).  
Figure 23: Past six month use and frequency of use of cocaine, nationally, 2000-2020 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
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Table 10: Past six month use of cocaine, by jurisdiction, 2000-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 63 15 13 6 20 22 18 13 
2001 84 40 28 8 27 32 13 28 
2002 79 18 17 12 26 17 10 15 
2003 53 13 13 9 13 10 - 16 
2004 47 10 10 - 6 15 10 10 
2005 60 20 15 8 16 19 10 11 
2006 67 8 19 12 8 10 8 9 
2007 63 18 22 - 7 16 9 15 
2008 58 18 24 - - 15 - 13 
2009 61 22 15 - 10 12 12 15 
2010 57 6 14 - 12 15 - 13 
2011 47 8 17 7 12 10 - 13 
2012 44 16 9 11 7 15 - - 
2013 41 16 11 - 9 15 7 11 
2014 32 15 10 8 7 7 - 9 
2015 34 12 9 - 13 11 - 8 
2016 25 8 10 6 6 10 - 9 
2017 21 18 12 11 10 10 9 9 
2018 26 14 15 11 10 12 6 9 
2019 21 15 10 6 16 12 9 10 
2020 23 19 17 16 14 18 - 19 
Note. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
Price, Perceived Purity and Availability 
Questions pertaining to the price, perceived purity and availability of cocaine were not asked of 
participants in 2020. For further information, please refer to the 2019 IDRS National Report.  
  

















Participants were asked about their recent (past six month) use of 
indoor-cultivated cannabis via a hydroponic system (‘hydro’) and 
outdoor-cultivated cannabis (‘bush’), as well as hashish and hash oil.  






Patterns of Consumption 
Recent Use (past 6 months) 
Over the course of monitoring, at least three in four participants nationally have reported recent use 
of cannabis. However, a significant decline was observed in 2020, with 67% reporting recent use 
(74% in 2019; p=0.004) (Figure 24). In all the jurisdictions, the per cent reporting recent cannabis use 
over the period of monitoring has declined over time (Table 11).   
Frequency of Use 
In 2020, median frequency of use in the past six months was 160 days (IQR=24-180), similar to 2019 
(130 days; IQR=24-180; p=0.749) (Figure 24). Just under half (48%) of those who had recently used 
cannabis reported daily use (46% in 2019; p=0.572).  
Routes of Administration 
Smoking remained the most common route of administration (97%; 99% in 2019; p=0.136). A smaller 
per cent reported inhaling/vaporising (8%; 9% in 2019; p=0.912) and swallowing (5%; 8% in 2019; 
p=0.073) cannabis.  
Quantity 
Of those who reported recent use and commented (n=330), the median typical amount used on last 
occasion was one gram (IQR=0.80-2.00; n=330; 1.00 gram in 2019; IQR=1.00-2.00; p=0.283) or two 
cones (IQR=1-4; n=56; 3 cones in 2019; IQR=2-5; p=0.043) or one joint (IQR=1-1; n=68; 1 joint in 
2019; IQR=1-2; p=0.103).  
Forms of Cannabis 
Of those who had used cannabis in the past six months and commented (n=555), 89% reported recent 
use of hydroponic cannabis (94% in 2019; p=0.011), and under two-fifths (39%) reported recent use 
of outdoor-grown ‘bush’ cannabis (54% in 2019; p<0.001). A smaller percentage reported having used 



















Figure 24: Past six month use and frequency of use of cannabis, nationally, 2000-2020 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Table 11: Past six month use of cannabis, by jurisdiction, 2000-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2000 72 84 85 90 88 90 84 84 
2001 83 85 88 94 85 91 81 82 
2002 80 89 87 91 85 98 83 82 
2003 79 86 88 88 80 81 83 76 
2004 80 85 81 87 83 84 75 75 
2005 80 89 86 87 80 76 79 76 
2006 80 90 83 88 77 80 84 85 
2007 79 83 83 87 81 69 83 84 
2008 80 80 74 86 75 64 78 82 
2009 79 81 79 89 61 72 79 69 
2010 72 81 81 79 66 70 72 77 
2011 81 87 85 78 69 71 71 79 
2012 72 81 85 81 61 79 71 70 
2013 80 75 80 71 61 61 67 67 
2014 77 74 75 82 75 69 62 70 
2015 79 81 76 73 74 60 72 60 
2016 76 69 77 74 73 70 72 64 
2017 79 76 71 73 73 73 59 70 
2018 76 79 70 81 70 77 60 67 
2019 73 79 76 76 79 72 72 65 
2020 64 77 69 72 67 66 60 64 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
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Price, Perceived Potency and Availability 
Price 
Consistent with previous years, the median price per gram of hydroponic cannabis nationally was $20 
(IQR=20-25; n=155; $20 in 2019; IQR=20-25; n=227; p=0.447), and $20 for bush (IQR=17-25; n=65; 
$20 in 2019; IQR=15-20; n=99; p=0.066). The price per ounce of hydroponic cannabis increased 
significantly compared to previous years ($300; IQR=250-350; n=119; $280 in 2019; IQR=240-300; 
n=113; p=0.020), as did the price per ounce of bush ($250; IQR=200-300; n=63; $200 in 2019; 
IQR=180-250; n=76; p=0.019) (Figure 25).   
Perceived Potency  
Of those who were able to comment (hydroponic: n=348; bush: n=157), almost half (49%) perceived 
hydroponic cannabis to be of ‘high’ potency, a significant decrease relative to 2019 (59%; p=0.008). 
In contrast, the per cent reporting bush as ‘high’ in potency was 32% (28% in 2019; p=0.340), with 
the larger per cent perceiving bush cannabis to be of ‘medium’ potency (44%; 48% in 2019; p=0.477) 
(Figure 26).  
Perceived Availability 
Participants who were able to comment on hydroponic cannabis (n=351) reported it to be ‘very easy’ 
(33%; 52% in 2019; p<0.001) or ‘easy’ (48%; 36% in 2019; p<0.001) to obtain in 2020. Reports of 
perceived bush availability (n=160) also indicated that bush tended to be ‘easy’ (44%; 37% in 2019; 
p=0.174) or ‘very easy’ (24%; 41% in 2019; p=0.001) to obtain, with one-quarter (25%) reporting it 
was ‘difficult’ to obtain (19% in 2019; p=0.205) (Figure 27). 
  







Figure 25: Median price of hydroponic (a) and bush (b) cannabis per ounce and gram, nationally, 2003-
2020 
 





(B) Bush cannabis 
 
Note. Among those who commented. From 2003 onwards hydroponic and bush cannabis data collected separately. No data available for 
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Figure 26: Current perceived potency of hydroponic (a) and bush (b) cannabis, nationally, 2004-2020 
 
(A) Hydroponic cannabis 
 
(B) Bush cannabis 
 
Note. The response ‘Don’t know’ was excluded from analysis. Hydroponic and bush cannabis data collected separately from 2004 
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Figure 27: Current perceived availability of hydroponic (a) and bush (b) cannabis, nationally, 2004-2020 
 
(A) Hydroponic cannabis 
 
(B) Bush cannabis 
 
Note. The response ‘Don’t know’ was excluded from analysis. * Hydroponic and bush cannabis data collected separately from 2004 
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The following section describes recent (past six month) use of 
pharmaceutical opioids amongst the sample. Terminology throughout 
refers to prescribed use: use of pharmaceutical opioids obtained by 
a prescription in the person’s name; non-prescribed use: use of 
pharmaceutical opioids obtained from a prescription in someone 
else’s name; and any use: use of pharmaceutical opioids obtained 
through either of the above means. Contact the Drug Trends team 
(drugtrends@unsw.edu.au) for information on price and perceived 
availability of non-prescribed pharmaceutical opioids. 
 








Any Recent Use (past 6 months): Methadone use (including liquid and tablets) has generally ranged 
between one-third and half of participants reporting any recent use over the course of monitoring. In 
2020, 43% of participants reported recent use of any methadone (prescribed and non-prescribed), a 
significant increase from 37% in 2019 (p=0.028; Figure 28). The per cent reporting any non-prescribed 
use has steadily been declining since 2015. Indeed, methadone use historically has largely consisted 
of prescribed use (34% in 2020; 28% in 2019; p=0.015), with the per cent reporting non-prescribed 
use peaking at 32% in 2008 and declining to 13% nationally in 2020, the lowest percentage reported 
since 2003 (Figure 28). The per cent reporting non-prescribed use varies by jurisdiction, and in 2020 
there was a significant decrease in the NT relative to 2019 (n≤5 in 2020 versus 13% in 2019; p=0.024) 
(Table 12). 
Frequency of Use: Frequency of non-prescribed methadone syrup use remained low and stable in 
2020 (5 days; IQR=2-30; 6 days in 2019; IQR=2-24; p=0.955) (Figure 28).  
Recent Injection: Of those who had recently use methadone syrup or tablets (n=375), over one-
quarter (26%) of participants reported recently injecting methadone, a significant decrease relative to 
2019 (42%; p<0.001). Participants in 2020 reported injecting methadone on a median of 22 days 
(IQR=3-51), stable from 2019 (12 days; IQR=2-50; p=0.420).  
Figure 28: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 
methadone, nationally, 2000-2020 
 
 
Note. Includes methadone syrup and tablets. Non-prescribed use not distinguished 2000-2002. Median days computed among those who 
reported recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 30 days to improve visibility 















29 30 28 30 31
32
27 25 26 26 24 24


































% Any Use % Non-Prescribed Use Median days (non-prescribed syrup)







Table 12: Past six month non-prescribed use of methadone, by jurisdiction, 2003-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 20 27 13 76 33 18 39 18 
2004 29 30 11 75 19 20 35 28 
2005 19 34 11 60 27 27 41 22 
2006 28 39 11 63 28 32 33 20 
2007 24 34 21 66 27 31 33 20 
2008 27 35 21 70 17 19 45 27 
2009 36 26 20 68 10 11 32 11 
2010 27 25 19 58 17 13 27 15 
2011 25 25 22 53 15 27 30 16 
2012 26 27 21 47 14 31 27 12 
2013 29 29 12 51 20 24 13 16 
2014 29 27 21 51 9 20 16 17 
2015 25 16 17 36 11 14 17 14 
2016 21 12 13 40 6 13 14 19 
2017 19 13 7 39 6 - 18 19 
2018 20 13 11 42 - 9 8 18 
2019 22 15 7 29 8 - 13 19 
2020 17 7 10 26 9 11 -* 20 
Note. Includes methadone syrup and tablets. - Values suppressed due to small cell size (n≤5 but not 0). From 2000-2002, the IDRS did 
not distinguish between prescribed and non-prescribed methadone use. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
Buprenorphine 
Any Recent Use (past 6 months): The per cent reporting recent buprenorphine use has declined 
from 2006 onwards (Figure 29). In 2020, eight per cent of the sample reported recent use of any 
buprenorphine, stable from eight per cent in 2019; both years being the lowest reported percentage 
of recent use. Three per cent reported prescribed use (4% in 2019; p=0.912), whereas 5% reported 
non-prescribed use (5% in 2019; p=0.912) (Figure 29).  
Frequency of Use: Median days of non-prescribed use in 2020 was 12 days (IQR=3-48; 5 days in 
2019; IQR=2-11; p=0.098).   
Recent Injection: Of those who had recently use buprenorphine (n=68), over three-fifths (62%) 
reported recently injecting buprenorphine, stable relative to 2019 (70%; p=0.434). Participants in 2020 
reported injecting buprenorphine on a median of 23 days (IQR=3-125), also stable from 2019 (7 days; 















Figure 29: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 
buprenorphine, nationally, 2002-2020 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 40 days to improve visibility of trends. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Table 13: Past six month non-prescribed use of buprenorphine, by jurisdiction, 2003-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2003 5 - 32 - 10 18 13 7 
2004 8 - 35 - 12 23 15 20 
2005 8 15 29 - 14 34 20 20 
2006 19 34 29 6 14 32 14 30 
2007 16 28 26 6 11 19 - 31 
2008 7 25 19 - 12 18 18 25 
2009 18 23 25 12 9 16 - 31 
2010 13 27 21 - 9 18 8 27 
2011 12 21 18 6 8 11 8 33 
2012 13 20 19 6 9 14 10 22 
2013 11 16 9 9 7 10 20 16 
2014 22 12 12 11 - 19 12 19 
2015 9 11 12 13 6 8 10 17 
2016 11 8 4 10 - 9 16 26 
2017 13 14 6 9 7 10 - 25 
2018 - 9 5 11 - 8 - 12 
2019 4 - - - 0 - - 15 
2020 5 0 0 11 - 9 0 14 
 
Note. In 2002, IDRS interview did not distinguish between prescribed and non-prescribed use. - Values suppressed due to small cell size 
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Any Recent Use (past 6 months): The per cent reporting recent buprenorphine-naloxone use has 
remained relatively stable over the past decade. In 2020, almost one-fifth (18%) of the sample 
reported recent use of any buprenorphine-naloxone (22% in 2019; p=0.053; Figure 30), with almost 
one-tenth (9%) reporting non-prescribed use, a significant decrease relative to 2019 (12%; p=0.014; 
Figure 30). Ten per cent reported recent prescribed use in 2020, stable from 2019 (11% in 2019; 
p=0.618). On a jurisdictional level, there was an increase in recent non-prescribed use in TAS (23% 
versus 7% in 2019; p=0.006) and a decrease in VIC (4% versus 10% in 2019; p=0.048) and the ACT 
(n≤5 versus 14% in 2019; p=0.011) (Table 14). 
Frequency of Use: Frequency of non-prescribed use remained relatively stable in 2020 at a median 
of 10 days (IQR=2-25; 6 days in 2019; IQR=2-24; p=0.528) (Figure 30).   
Recent Injection: Of those who had recently used buprenorphine-naloxone (n=157), over one-third 
(35%) of participants reported injecting it, a significant decrease from 48% in 2019 (p=0.017). 
Participants reported injecting buprenorphine-naloxone on a median of 24 days (IQR=2-90) in the 
past six months (10 days in 2019; IQR=3-72; p=0.589).   
Figure 30: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 
buprenorphine-naloxone, nationally, 2006-2020 
 
 
Note. From 2006-2011 participants were asked about the use of buprenorphine-naloxone tablet; from 2012-2015 participants were asked 
about the use of buprenorphine-naloxone tablet and film; from 2016-2019 participants were asked about the use of buprenorphine–
naloxone film only. Median days of non-prescribed use computed among those who reported recent use (maximum 180 days), and only 
reported from 2012 onwards to capture film use. Median days rounded to the nearest whole number. Y axis reduced to 30 days to 
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Table 14: Past six month non-prescribed use of buprenorphine-naloxone (any form), by jurisdiction, 2006-
2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2006 - - 5 - - 9 - 7 
2007 - 6 13 - - 15 - 24 
2008 - 10 18 - - 12 - 16 
2009 6 11 14 - 9 28 8 22 
2010 - 12 24 - 8 17 15 21 
2011 8 12 29 - - 14 14 11 
2012# 9 9 23 11 18 22 8 15 
2013 9 11 17 9 9 22 19 22 
2014 15 16 15 11 9 18 20 16 
2015 11 12 17 13 15 19 22 27 
2016 11 7 14 7 6 - 9 23 
2017^ 14 13 11 14 14 16 10 24 
2018^ 9 16 12 12 - 7 - 18 
2019 11 14 10 7 8 16 10 22 
2020 - -* 4* 23** 11 12 - 15 
Note. Data collected from 2006 onwards. # Includes ‘tablet’ and ‘film’ forms from 2012-2016. ̂  Includes only ‘film’ form from 2017. - Values 
suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
Morphine 
Any Recent Use (past 6 months): After remaining relatively stable from 2001-2007, the per cent 
reporting recent morphine use has been declining from 2008 onwards (Figure 31). In 2020, 19% of 
the national sample had recently used any morphine (22% in 2019; p=0.100), the lowest percentage 
reporting recent use since the commencement of monitoring. Nationally, this per cent mostly 
comprised non-prescribed use (15% in 2020; 18% in 2019; p=0.109), with non-prescribed use lowest 
in the NSW sample (7%) and highest in the TAS sample (38%) (Table 15). Four per cent of the 
national sample in 2020 reported recent prescribed use (6% in 2019; p=0.075). 
Frequency of Use: Frequency of non-prescribed morphine use has fluctuated over time, though 
remained stable in 2020 at a median of 12 days (IQR=3-90) (12 days in 2019; IQR=3-72; p=0.635) 
(Figure 31).  
Recent Injection: Of those who had recently used morphine (n=165), the majority (85%) reported 
injecting any form, a decline relative to 2019 (93% in 2019; p=0.033). Those who injected did so on a 
median of 12 days (IQR=3-90) in the six months preceding interview, stable from 15 days in 2019 
(IQR=3-78; p=0.636).   
  






Figure 31: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 
morphine, nationally, 2001-2020 
 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 30 days to improve visibility of trends. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
  
Table 15: Past six month non-prescribed use of morphine, by jurisdiction, 2006-2020  
 
% NSW ACT VIC TAS SA WA NT QLD 
2006 31 52 31 58 48 52 70 51 
2007 34 53 37 67 41 45 73 57 
2008 31 35 40 81 30 31 85 51 
2009 28 38 31 81 22 33 61 38 
2010 31 36 30 73 24 28 89 38 
2011 21 30 33 73 20 33 72 39 
2012 21 30 27 64 23 43 69 34 
2013 19 23 20 65 22 37 74 38 
2014 25 12 24 71 20 27 80 32 
2015 19 20 13 47 20 19 69 29 
2016 16 12 10 51 18 16 71 33 
2017 16 21 7 42 12 18 60 26 
2018 17 10 10 47 7 14 54 29 
2019 13 11 9 26 10 15 40 28 
2020 7 8 8 38 11 18 32 21 
Note. From 2001-2005, IDRS did not distinguish between prescribed and non-prescribed morphine. - Values suppressed due to small cell 
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Any Recent Use (past 6 months): After a gradual increase from 2005 to 2012, the per cent reporting 
recent oxycodone use has been declining in the years following (Figure 32). In 2020, 14% of the 
national sample had recently used any oxycodone, a significant decrease relative to 2019 (18%; 
p=0.036). Eleven per cent of the sample reported non-prescribed use, also a significant decline from 
15% in 2019 (p=0.015). The per cent reporting non-prescribed oxycodone use has declined across 
all jurisdictions from 2012 onwards, and significantly so in 2020 for NSW, relative to 2019 (21% versus 
9%; p=0.006) (Table 16).  
Frequency of Use: In 2020, participants reported using non-prescribed oxycodone on a median of 
four days (IQR=2-12), stable from five days in 2019 (IQR=2-24, p=0.163).  
Recent Injection: Of those who had recently used oxycodone (n=120), over three-fifths (63%) of 
participants reported injecting any form of oxycodone (69% in 2019; p=0.430) on a median of five 
days (IQR=2-24) in the past six months, stable from seven days (IQR=2-25) in 2019 (p=0.386).   
Figure 32: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 




Note. From 2005-2015 participants were asked about any oxycodone; from 2016-2018, oxycodone was broken down into three types: 
tamper resistant (‘OP’), non-tamper proof (generic) and ‘other oxycodone’ (median days non-prescribed use missing 2016-2018). In 2019, 
oxycodone was broken down into four types: tamper resistant (‘OP’), non-tamper proof (generic), ‘other oxycodone’ and oxycodone-
naloxone. Median days of non-prescribed use computed among those who reported recent use (maximum 180 days). Median days 
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Table 16: Past six month non-prescribed use of oxycodone, by jurisdiction, 2005-2020 
 
% NSW ACT VIC TAS SA WA NT QLD 
2005 14 14 16 30 11 39 11 16 
2006 18 22 24 29 20 42 7 21 
2007 26 23 28 36 20 44 11 39 
2008 27 27 25 53 15 23 28 26 
2009 27 27 25 56 9 29 35 34 
2010 33 13 28 60 17 20 22 26 
2011 34 23 37 45 23 30 26 34 
2012 46 34 26 56 26 48 19 29 
2013 40 17 23 61 18 33 23 37 
2014 40 16 22 47 21 27 22 38 
2015 21 15 19 27 25 18 23 24 
2016 23 12 10 28 16 17 18 22 
2017 27 9 8 29 13 14 14 18 
2018 16 10 10 28 - 15 11 18 
2019 21 14 5 22 13 11 12 20 
2020 9** 8 7 24 11 8 9 15 
Note. Data on oxycodone use not collected from 2000-2005. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; 




Any Recent Use (past 6 months): The per cent reporting recent use of fentanyl has remained low 
since monitoring began (Figure 33), with the lowest per cent of participants reporting recent use in 
2020 (7%), a significant decrease from 11% in 2019 (p=0.016) (Figure 33). Six per cent reported non-
prescribed use (9% in 2019; p=0.081), with one per cent reporting prescribed use (2% in 2019; 
p=0.050). Non-prescribed use was highest in the WA and SA samples (11% and 10%, respectively), 
followed by 9% in the ACT and 8% in NSW (Table 17).  
Frequency of Use: In 2020, participants reported non-prescribed use on a median of two days 
(IQR=1-7) in the past six months (5 days in 2019; IQR=2-11; p=0.023).   
Recent Injection: Of those who had recently used fentanyl (n=64), the majority (91%) reported 
injecting any form of fentanyl on a median of two days (IQR=1-6) in the past six months (88% in 2019; 
p=0.721; 5 days in 2019; IQR=2-14; p=0.016).   
  






Figure 33: Past six month use (prescribed and non-prescribed) and frequency of use of non-prescribed 
fentanyl, nationally, 2013-2020 
 
 
Note. Data on fentanyl use not collected from 2000-2012, and data on any non-prescribed use not collected 2013-2017. For the first time 
in 2018, use was captured as prescribed versus non-prescribed. Median days computed among those who reported recent use 
(maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 10 days to improve visibility of trends. 
*p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
 
Table 17: Past six month non-prescribed use of fentanyl, by jurisdiction, 2018-2020  
 
% NSW ACT VIC TAS SA WA NT QLD 
2018 6 6 8 0 - 8 - 16 
2019 11 10 7 - - 9 13 13 
2020 8 9 - - 10 11 -* -* 
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Other Opioids  
Participants were asked about prescribed and non-prescribed use of other opioids in 2020 (Table 18). 
In 2020, one-tenth (10%) of participants reported any recent use of codeine, with 7% reporting 
prescribed use, a significant decrease from 14% in 2019 (p<0.001), and four per cent reporting non-
prescribed use, also a significant decrease from 2019 (9%; p<0.001). Seven per cent of participants 
reported recent injection, stable from 5% in 2019 (p=0.902).  
In 2020, there was a significant decrease in both prescribed use (4%; 9% in 2019; p<0.001) and non-
prescribed use (4%; 7% in 2019; p=0.001) of tramadol. Small numbers (n≤5) reported recently 
injecting tramadol; therefore, numbers are suppressed. Very few participants (n=11) reported any 
recent use of tapentadol. For further information, please refer to the 2019 IDRS National Report. 
Table 18: Past six month use of other opioids, nationally, 2019-2020 





Codeine   
Any prescribed use 14 7*** 
Any non-prescribed use 9 4*** 
Any injection 5 7 
Tramadol   
Any prescribed use 10 4*** 
Any non-prescribed use 7 4** 
Any injection 9 - 
Tapentadol   
Any prescribed use - 1 
Any non-prescribed use 1 - 
Any injection - - 






















Participants were asked about their recent (past six month) use of 
various other drugs, including use of new psychoactive substances, 
non-prescribed use (i.e., use of a medicine obtained from a 
prescription in someone else’s name) of other pharmaceutical drugs, 
and use of licit substances (e.g., alcohol, tobacco). 






New Psychoactive Substances (NPS) 
NPS are often defined as substances which do not fall under international drug control, but which may 
pose a public health threat. However, there is no universally accepted definition, and in practicality 
the term has come to include drugs which have previously not been well-established in recreational 
drug markets.  
Recent Use (past 6 months): In 2020, the per cent reporting any NPS use decreased slightly among 
the national sample, with 8% reporting recent use (11% in 2019; p=0.040) (Table 19). ‘New’ drugs 
that mimic the effects of cannabis were the most commonly used NPS (5%), although consumers 
reported infrequent use (median 3 days; IQR=1-6). A small per cent (1%) reported use of new drugs 
that mimic the effects of opioids.  
Table 19: Past six month use of new psychoactive substances, nationally, 2013-2020 
 
% 2013 2014 2015 2016 2017 2018 2019 2020 
 N=887 N=898 N=888 N=877 N=888 N=905 N=902 N=884 
‘New’ drugs that mimic the effects of opioids / / / / - - 2 1 
‘New’ drugs that mimic the effects of ecstasy / / / / 1 1 2 -* 
‘New’ drugs that mimic the effects of 
amphetamine or cocaine 4 4 3 4 / 2 1 2 
‘New’ drugs that mimic the effects of cannabis 9 8 8 8 5 5 6 5 
‘New’ drugs that mimic the effects of psychedelic 
drugs / / / / 1 2 1 1 
‘New’ drugs that mimic the effects of 
benzodiazepines / / / / / - 1 - 
Any of the above 12 11 10 11 8 11 11 8* 
Note. - Values suppressed due to small cell size (n≤5 but not 0). / denotes that this item was not asked in these years. # In 2017 
participants were asked about use of ‘new drugs that mimic the effects of ecstasy or psychedelic drugs’. *p<0.050; **p<0.010; ***p<0.001 
for 2019 versus 2020. 
 
Non-Prescribed Pharmaceutical Drugs 
Benzodiazepines 
Any Recent Use (past 6 months): The per cent reporting non-prescribed benzodiazepine use has 
decreased, from 46% in 2007 when monitoring commenced to 31% in 2020 (32% in 2019; p=0.646) 
(Figure 34). In the total 2020 sample, 15% reported use of non-prescribed alprazolam (17% in 2019; 
p=0.365) and 24% reported use of non-prescribed other benzodiazepines (24% in 2019; p=0.881). 
Frequency of Use: In 2020, consumers reported a median of three days (IQR=2-10; 6 days in 2019; 
IQR=2-22; p<0.001) and 10 days (IQR=3-24; 7 days in 2019; IQR=3-30; p=0.881) of non-prescribed 
use of alprazolam and other benzodiazepines, respectively. 
Recent Injection: In 2020, 6% of participants who had recently used non-prescribed 
benzodiazepines reported injecting as a route of administration (6% in 2019).  Additionally, 4% of 
participants who had recently used any benzodiazepines (including alprazolam) (prescribed or non-
prescribed) reported injecting as a route of administration (4% in 2019).  







Any Recent Use (past 6 months): Non-prescribed use of pharmaceutical stimulants (e.g., 
dexamphetamine, methylphenidate, modafinil) has decreased since monitoring began (Figure 34). 
One-fifth (18%) reported recent use in 2006, declining to 8% in 2020 (7% in 2019; p=0.363).  
Frequency of Use: Frequency of non-prescribed use decreased from five days in 2019 (IQR=2-10) 
to three days in 2020 (IQR=1-12; p=0.047).  
Recent Injection: Two-fifths (42%) of those who had recently used non-prescribed pharmaceutical 
stimulants (equivalent to 3% of the total sample) reported that they had injected it, significantly lower 
relative to 2019 (63%; p=0.023) on a median of two days (IQR=2-10; 4 days in 2019; IQR=2-10; 
p=0.234).  
Antipsychotics 
Any Recent Use (past 6 months): The per cent of the sample reporting recent use of non-prescribed 
antipsychotics (asked as ‘Seroquel’ 2011-2018) has ranged between 9% and 15% of the sample since 
monitoring began in 2011 (2020: 6%; 9% in 2019; p=0.013; Figure 34).  
Frequency of Use: Non-prescribed use remained infrequent amongst consumers in 2020 (median 4 
days; IQR=2-10; 5 days in 2019; IQR=2-21; p=0.990).  
Pregabalin 
Any Recent Use (past 6 months): In 2020, 14% of the national sample had used non-prescribed 
pregabalin in the six months preceding interview, significantly lower compared to 2019 (18%; 
p=0.013) (Figure 34), with the highest per cent reporting recent use observed in the TAS and WA 
samples (27% and 21%, respectively).  
Frequency of Use: Non-prescribed use was infrequent amongst recent consumers in 2020, with a 
reported median of six days of use (IQR=2-24), consistent with 2019 reports (median 4 days; IQR=2-
14; p=0.114).  
Recent Injection: Of those who had recently used non-prescribed pregabalin, 11% reported recent 
injection, a significant increase compared to 2019 (n≤5; p=0.003).  
  






Figure 34: Past six month use of non-prescribed pharmaceutical drugs, nationally, 2000-2020 
Note. Non-prescribed use is reported. Participants were first asked about anti-psychotics in 2011 (asked as ‘Seroquel’ 2011-2018) and 
pregabalin in 2018. Pharmaceutical stimulants were separated into prescribed and non-prescribed from 2006 onwards, and 
benzodiazepines were separated into prescribed and non-prescribed in 2007; *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
Licit and Other Drugs 
Steroids 
Recent Use (past 6 months): Reports of recent use of non-prescribed steroids have remained 
consistently low (between 1% and 3%) since monitoring began in 2010.  
Alcohol 
Recent Use (past 6 months): Fifty-four per cent of the sample reported recent use of alcohol in 2020, 
a significant decrease from 59% in 2019 (p=0.024) (Figure 35).  
Frequency of Use: Median frequency of use amongst consumers in 2020 was 24 days (IQR=6-96; 
24 days in 2019; IQR=6-90; p=0.114), with 19% of recent consumers in 2020 reporting daily use (14% 
in 2019; p=0.040). 
Tobacco 
Recent Use (past 6 months): Tobacco use has remained relatively high since the IDRS began, 
though 89% of the national sample reported recent use in 2020, a significant decrease from 94% in 
2019 (p<0.001; Figure 35).  
Frequency of Use: Median frequency of use was 180 days (IQR=180-180 days; 180 days in 2019; 
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Any Recent Use (past 6 months): E-cigarette use had slowly increased until 2019 (21%), following 
which there was a decline (13% in 2020; p<0.001) (Figure 35). 
Frequency of Use: Median frequency of use increased from five days in 2019 (IQR=2-30) to 20 days 
in 2020 (IQR=3-160; p=0.002)), with 24% of recent consumers reporting daily use, also an increase 
from 2019 (14%; p=0.037). 
Forms Used: Among recent consumers and those able to comment (n=112), the majority (74%) 
reported using e-cigarettes containing nicotine (79% in 2019; p=0.343), followed by 5% who reported 
using both nicotine and cannabis (7% in 2019; p=0.690) Seventeen per cent reported using neither 
cannabis nor nicotine (13% in 2019; p=0.347) and a small number reported just cannabis (n≤5; n≤5 
in 2019; p=0.284). 
Reason for Use: Nearly three-fifths (57%) of recent consumers reported that they did not use e-
cigarettes as a smoking cessation tool in 2020 (52% in 2019; p=0.411). 
GHB/GBL/1, 4-BD 
Any Recent Use (past 6 months): In 2020, 10% of the sample reported recent use of GHB/GBL/1,4-
BD (question not asked in 2019, hence no comparison is made).  
 
Recent Injection: A small number reported recent injection of GHB/GBL/1,4-BD in 2020 (n≤5).  
 
 
Figure 35: Past six month use of licit drugs, nationally, 2000-2020 
















































Participants were asked about various drug-related harms and 
associated behaviours, including non-fatal overdose, injecting risk, 
drug treatment, mental health and crime. It should be noted that the 
following data refer to participants’ understandings of these 
behaviours (e.g., may not represent medical diagnoses in the case of 
reporting on health conditions).  








There has been some variation in the way questions about overdose have been asked over the years.  
In 2020, participants were asked about their past 12-month experience of overdose where symptoms 
aligned with examples provided and effects were outside their normal experience or they felt 
professional assistance may have been helpful. We specifically asked about: 
• Opioid overdose (e.g. reduced level of consciousness, respiratory depression, turning blue, 
collapsing and being unable to be roused). Participants who reported this experience were 
asked to identify all opioids involved in such events in the past 12 months; 
• Non-opioid overdose (e.g. nausea, vomiting, chest pain, tremors, increased body 
temperature, increased heart rate, seizure, extreme paranoia, extreme anxiety, panic, extreme 
agitation, hallucinations). Drugs other than opioids were split into the following data coding: 
- Stimulant overdose: Stimulant drugs include ecstasy, methamphetamine, cocaine, MDA, 
methylone, mephedrone, pharmaceutical stimulants and stimulant NPS (e.g. MDPV, 
Alpha PVP);  
- Other drug overdose: ‘Other drugs’ include (but are not limited to) alcohol, cannabis, 
GHB/GBL/1,4-BD, amyl nitrite/alkyl nitrite, benzodiazepines and LSD.  
 
In 2019, participants were explicitly queried about stimulant and ‘other drug’ overdose. 
It is important to note that events reported across the drug types may not be unique given high rates 
of polysubstance use amongst the sample. Each year we compute the total per cent of participants 
who have experienced any past 12-month overdose event by looking for any endorsement across the 
drug types queried (see below) but note that estimates may vary over time because of changed 
nuance in asking by drug type.  
After some fluctuations from 2000-2006 (likely due to differences in the way questions regarding 
overdose were asked), the per cent reporting any past 12 month non-fatal overdose remained 
relatively stable from 2007-2017. After a slight increase in 2018 and 2019 (20% and 21%, 
respectively; p=0.691), the per cent reporting any past 12-month non-fatal overdose in 2020 remained 
relatively stable (18%; p=0.054) (Figure 36). In 2020, the per cent reporting any past 12-month non-
fatal overdose was highest in SA (25%) closely followed by QLD (24%) and lowest in the NT (no 
participants reported overdose) (Table 20).  
Thirteen per cent reported a non-fatal overdose following opioid use in the past 12 months (15% 
in 2019; p=0.205) (Table 20), whilst 6% reported a non-fatal overdose following stimulant use in 
the past 12 months (7% in 2019; p=0.216) (Table 20).  
The most commonly cited substance involved in past year non-fatal overdoses was heroin (11% of 
total sample in 2020; Table 20). In 2020, participants who had overdosed on heroin had done so on 
a median of two occasions (IQR=1-3) in the last 12 months. Among those that had overdosed on 
heroin in the past year and commented (n=98), 37% reported that an ambulance had attended their 
most recent overdose, 48% reported receiving Narcan®, 16% were admitted to an emergency 
department, and 6% reported receiving cardiopulmonary resuscitation from a friend/partner/peer. 
Twenty-seven per cent reported not receiving any treatment. The most commonly cited drugs involved 






in participants’ most recent heroin overdose were benzodiazepines (including alprazolam, 30%), 
alcohol (26%), crystal methamphetamine (11%) and cannabis (9%).  
Please contact the Drug Trends team (drugtrends@unsw.edu.au) to request further findings 
regarding non-fatal overdose in the IDRS sample. 
Figure 36: Past 12-month any non-fatal overdose, nationally, 2000-2020 
 
 
Note. Estimates from 2000-2005 refer to heroin and morphine non-fatal overdose only. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 
2020. 
 
Table 20: Past 12-month non-fatal overdose by drug type, nationally and by jurisdiction, 2019-2020 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 2019 2020         
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Note. Participants reported on whether they had overdosed following use of the specific substances; other substances may have been 
involved on the occasion(s) that participants refer to.  – Values suppressed due to small numbers (n≤5 but not 0). N is the number who 



































Naloxone Program and Distribution 
Naloxone is a short-acting opioid antagonist that has been used for over 40 years to reverse the 
effects of opioids. In 2012, a take-home naloxone program commenced in the ACT (followed by NSW, 
VIC, and WA) through which naloxone was made available to peers and family members of people 
who inject drugs for the reversal of opioid overdose. In early 2016, the Australian Therapeutic Goods 
Administration (TGA) placed ‘naloxone when used for the treatment of opioid overdose’ on a dual 
listing of Schedule 3 and Schedule 4, meaning naloxone can be purchased OTC at pharmacies 
without a prescription, and at a reduced cost via prescription. In 2020, under the take home naloxone 
pilot program, naloxone was made available free of charge and without a prescription in NSW, SA 
and WA. Furthermore, naloxone nasal spray (Nyxoid) is now available in Australia as a PBS-listing, 
which is expected to increase use of naloxone in the community.  
Awareness of Naloxone: From 2013-2020, there has been no significant change in the per cent of 
the national sample who have heard of naloxone, with over four in five participants reporting 
awareness of naloxone. However, a significant decrease transpired in the per cent of participants who 
had heard of naloxone in the NT sample (49% in 2020; 66% in 2019; p=0.030) and in the QLD sample 
(85% in 2020; 94% in 2019; p=0.044) (Table 21).  
Awareness of Take-Home Programs (training program): There has been an increase in the 
proportion who have heard about take-home naloxone programs. In 2020, nearly two-thirds of 
participants (65%) had heard about the take-home naloxone programs, an increase relative to 2019 
(57%; p=0.001). In 2020, knowledge regarding the take-home naloxone program (and participation in 
this program) was highest in the VIC and the ACT samples (78% and 81%, respectively). In saying 
this, significant increases were observed in NSW (75%), TAS (45%) and SA (39%) relative to reports 
from 2019 (64%; p=0.034, 24%; p=0.007 and 22%; p=0.012). 
Participation in Training Programs: Further, in 2020, there was a significant increase in those who 
had been trained in how to administer naloxone in their lifetime (34%; 29% in 2019; p=0.037; Figure 
37). This increase in the per cent reporting training was most evident in the NSW sample (54%; 40% 
in 2019; p=0.017) and the TAS sample (12%; n≤5 in 2019; p=0.010). Half of those participating in the 
naloxone training program had completed their last naloxone training via a needle and syringe 
program (NSP; 49%), followed by 29% via a drug treatment service, and 17% via a health service.  
Accessed Naloxone: In 2020, 41% of the total sample reported having ever accessed naloxone, 
with 4% having tried to access naloxone but had been unsuccessful. Out of those that had never 
accessed naloxone (n=552), the reason why they had not accessed it were ‘didn’t consider myself/my 
peers at risk of overdose’ (26%), ‘don’t use opioids’ (18%) and ‘didn’t know you could access 
naloxone’ (13%).  
 
Of those who reported to have accessed naloxone and could respond (n=329), on the last occasion 
nearly two-thirds (63%) received the intramuscular naloxone and over one-third (37%) received 
intranasal naloxone. On the last occasion two-fifths (42%) accessed naloxone via a needle and 
syringe program (NSP), followed by a pharmacy (21%) and a drug treatment service (20%). The 
majority (94%) did not have to pay the last time they accessed naloxone. Of those that had accessed 
naloxone, half (50%) reported that they ‘always’ had naloxone on hand when using opioids in the past 
month, followed by 16% reporting ‘never’, 15% ‘often’, 8% ‘sometimes’ and 5% ‘rarely’.  
 
Use of Naloxone to Reverse Overdose: In 2020, of those that reported to have heard about 
naloxone and could respond (n=727), one-quarter (27%) reported that they had resuscitated someone 






using narcan/naloxone at least once in their lifetime. Of those who reported past year opioid overdose 
and could respond (n=106), two-fifths (42%) reported that they had been resuscitated by a peer using 
narcan/naloxone. 
In 2020, 5% of the national sample reported that they had ever been resuscitated with naloxone by a 
peer (11% in 2019; p<0.001) and 23% reported to have ever resuscitated someone who had 
overdosed using naloxone (33% in 2019; p<0.001). 
Figure 37: Take-home naloxone program and distribution, nationally, 2013-2020 
 
 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
 
Table 21: Awareness of take-home naloxone program and distribution, by jurisdiction, 2020 
 
 NSW ACT VIC TAS SA WA NT QLD 


























































Injecting Risk Behaviours and Harms 
Injecting Risk Behaviours 
In 2020, 5% nationally reported receptive sharing (a decrease from 8% in 2019; p=0.027) and 9% 
reporting distributive sharing (11% in 2019; p=0.212) in the past month. The per cent who have shared 
other injecting equipment (e.g. spoons, tourniquet, water, and filters) in the past month has declined 
substantially since monitoring began until 2020 when it increased significantly to 25% (5% in 2019; 
p<0.001) (Figure 38). The per cent of the sample who reported re-using their own needles in the past 
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month also declined from 2000 to 2018, however remained stable in 2020 relative to 2019 (2020: 
44%; 44% in 2019; p=0.994).  
One-third (32%) of the 2020 sample reported that they had injected someone else after injecting 
themselves (35% in 2019; p=0.190) and 17% were injected by someone else who had previously 
injected in the past month, a significant decrease from 21% in 2019 (p=0.040).  
Consistent with previous years, most participants (83%) in the national sample reported that they had 
last injected in a private home (77% in 2019; p=0.001; Table 22). Five per cent of Sydney participants 
(9% in 2019; p=0.100) and 8% of Melbourne participants (13% in 2019; p=0.231) reported last 
injecting at the Medically Supervised Injecting Centre/Room in their city.   




Note. Data collection for ‘reused own needle’ started in 2008. Borrowed (receptive): used a needle after someone else. Lent (distributive): 




































Borrowed needles Lent needles Shared other equipment Re-used needle







Table 22: Sharing needles and injecting equipment in the past month, nationally and by jurisdiction, 2019-
2020 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=893 N=884 N=155 N=100 N=179 N=74 N=100 N=100 N=78 N=98 










































































































































% Location of 
last injection N=888 N=878 N=154 N=100 N=178 N=72 N=100 N=98 N=78 N=98 
Private home 77 83** 85 91 71 89 89 80 85 83 
Car 4 5 - 7 4 - - 9 - 7 
Street/car 
park/beach 7 5 5 0 10 - - - 13 - 





4 3 5 / 8 / / / / / 
Other 2 1 - 0 - 0 0 - 0 0 
Note. ^ Includes spoons, water, tourniquets and filters; excludes needles/syringes. ~ New or used needle. Borrowed (receptive): used a 
needle after someone else. Lent (distributive): somebody else used a needle after them. - Values suppressed due to small cell size (n≤5 











Self-Reported Injection-Related Health Problems 
In 2020, 29% of the national sample reported having an injection-related health issue in the month 
preceding interview, significantly lower relative to 2019 (45%; p<0.001) (Table 23). The most common 
injection-related health issues reported by participants comprised nerve damage (12%), followed by 
a dirty hit (8%) and infection/abscess (8%), all significantly lower compared to 2019 (20%; p<0.001, 
22%; p<0.001 and 14%; p<0.001, respectively).  
Table 23: Injection-related issues in the past month, nationally and by jurisdiction, 2019-2020 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=865 N=879 N=155 N=100 N=178 N=72 N=100 N=100 N=78 N=96 
 2019 2020         
% Artery injection 15 7*** 8 - 11 - 9 10 - - 
% Nerve damage 20 12*** 10 9 15 - 13 13 - 23 
% Any thrombosis 9 7 9 - 10 - 8 6 - - 
Blood clot 7 6 7 - 9 - 8 - - - 
Deep vein 
thrombosis 2 2 - 0 - 0 - - - - 
% Infection/ abscess 14 8*** 7 8 8 - 15 9 - 8 
Skin abscess 12 7*** 6 - 7 - 14 7 0 7 
Osteomyelitis/Sepsis/ 
Septic arthritis 2 2 - - - 0 - - 0 - 
Endocarditis 3 -*** 0 - - 0 0 0 - 0 
% Dirty hit 22 8*** 10 6 11 - 8 11 0 9 
% Any injection 
related problem 45 29*** 31 24 36 21 35 33 - 33 
Note. In 2020, ‘sepsis’ and osteomyelitis were combined. - Values suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; 











In 2020, nearly half of participants (48%) reported that they were currently in any drug treatment for 
their substance use (most commonly methadone), significantly more so than in 2019 (42% in 2019; 
p=0.028) (Table 24).  
In 2020, of those not currently in treatment (n=463), 12% reported having difficulties accessing 
treatment in the past six months and 19% reported wanting to access treatment but not trying to. 
Among the participants that experienced difficulties accessing treatment (n=55), methamphetamine 
(45%) and heroin (39%) were the main substances for which participants intended to seek treatment. 
Residential rehabilitation/therapeutic community (39%), detoxification (22%) and opioid substitution 
program (10%) were the main services that people had tried to access.  
 
Table 24: Current drug treatment, nationally and by jurisdiction, 2019-2020 
 
 National NSW ACT VIC TAS SA WA NT QLD 
 N=901 N=884 N=155 N=100 N=179 N=74 N=100 N=100 N=78 N=98 
 2019 2020         
% Current drug treatment 42 48* 56 71 58 30 38 48 8 47 
Methadone 25 31** 44 52 40 14 20 24 - 21 
Buprenorphine 2 2 0 - - - 0 0 - 8 
Buprenorphine-naloxone 9 8 5 9 7 - 10 14 - 11 
Buprenorphine depot injection 0 2** - - - 0 - - 0 0 
Drug counselling 9 11 17 13 9 - 8 17 - 8 
Other 5 4 5 - 4 0 - - 0 - 
Note. Numbers suppressed when n≤5 (but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020 for national estimates. 






Mental Health  
In 2020, 47% of the sample self-reported that they had experienced a mental health problem in the 
preceding six months, stable from 2019 (47%) (Figure 39). Amongst this group, the most commonly 
reported problems were depression (70%; 70% in 2019; p=0.934) and anxiety (55%; 61% in 2019; 
p=0.092). Smaller proportions of this group reported post-traumatic stress disorder (22%), bipolar 
disorder (13%), and schizophrenia (11%).  
One-quarter of the total sample (25%; 53% of those who reported a mental health problem) had seen 
a mental health professional during the past six months, significantly fewer when compared to 2019 
(67% in 2019; p<0.001). Three-quarters (73%) of those who reported having seen a health 
professional about a mental health problem had been prescribed medication for their mental health 
problem in the preceding six months (72% in 2019; p=0.842).  




Note. Stacked bar graph of % who self-reported a mental health problem, disaggregated by the per cent who reported attending a health 
professional versus the per cent who have not. *p<0.050; **p<0.010; ***p<0.001 for 2019 versus 2020. 
32 32 27 33 29 31
38 34
25






































The per cent of participants reporting past month criminal activity declined from 2000 to 2010, 
stabilising from 2010 onwards. Property crime and selling drugs for cash profit remain the most 
common self-reported crimes in the month preceding interview in 2020 (23% and 25%, respectively) 
(Figure 40). Though numbers remain low, a significant decrease was observed in those reporting 
violent crime, from 7% in 2019 to 4% in 2020 (p=0.006). In 2020, 12% reported being a victim of a 
crime involving violence (e.g., assault), a significant decrease relative to 2019 (17%; p=0.007).  
In 2020, 26% of the sample had been arrested in the past year, significantly lower than 34% in 2019 
(p<0.001). This ranged from 21% in the NT sample to 35% in the TAS sample. Over half of the national 
sample (56%) reported a lifetime prison history in 2020, a significant decrease from 2019 (62%; 
p=0.009). This ranged from 43% in the WA and SA samples, respectively, to 70% in the NSW and 
NT samples, respectively.  
Figure 40: Self-reported criminal activity in the past month, nationally, 2000-2020 
 
 
Note. ‘Any crime’ comprises the per cent who report any property crime, drug dealing, fraud and/or violent crime in the past month. 
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